<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment for psychotic depression - Kruizinga, J - 2021 | Cochrane Library</title> <meta content="Pharmacological treatment for psychotic depression - Kruizinga, J - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment for psychotic depression - Kruizinga, J - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004044.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment for psychotic depression" name="citation_title"/> <meta content="Jacolien Kruizinga" name="citation_author"/> <meta content="PsyQ Emmen" name="citation_author_institution"/> <meta content="Edith Liemburg" name="citation_author"/> <meta content="University of Groningen" name="citation_author_institution"/> <meta content="Huibert Burger" name="citation_author"/> <meta content="Andrea Cipriani" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="John Geddes" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Lindsay Robertson" name="citation_author"/> <meta content="Beatrix Vogelaar" name="citation_author"/> <meta content="Trimbos Institute" name="citation_author_institution"/> <meta content="Willem A Nolen" name="citation_author"/> <meta content="University Medical Center Groningen, University of Groningen" name="citation_author_institution"/> <meta content="wnolen@planet.nl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004044.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents [therapeutic use]; Depression [drug therapy]; *Depressive Disorder, Major [drug therapy]; *Psychotic Disorders [drug therapy]; Systematic Reviews as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004044.pub5&amp;doi=10.1002/14651858.CD004044.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004044\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004044\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","pt","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004044.pub5",title:"Pharmacological treatment for psychotic depression",firstPublishedDate:"Dec 7, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004044.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004044.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004044.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004044.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004044.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004044.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004044.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004044.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004044.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004044.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8437 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004044.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0137"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-sec-0131"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/appendices#CD004044-sec-0142"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/supinfo/CD004044StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/supinfo/CD004044StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment for psychotic depression</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0004">Jacolien Kruizinga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0005">Edith Liemburg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0006">Huibert Burger</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0007">Andrea Cipriani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0008">John Geddes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0009">Lindsay Robertson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0010">Beatrix Vogelaar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information#CD004044-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Willem A Nolen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information/en#CD004044-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004044.pub5">https://doi.org/10.1002/14651858.CD004044.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004044-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004044-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004044-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004044-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004044-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004044-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004044-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004044-abs-0001" lang="en"> <section id="CD004044-sec-0001"> <h3 class="title" id="CD004044-sec-0001">Background</h3> <p>Evidence is limited regarding the most effective pharmacological treatment for psychotic depression: monotherapy with an antidepressant, monotherapy with an antipsychotic, another treatment (e.g. mifepristone), or combination of an antidepressant plus an antipsychotic. This is an update of a review first published in 2005 and last updated in 2015. </p> </section> <section id="CD004044-sec-0002"> <h3 class="title" id="CD004044-sec-0002">Objectives</h3> <p>1. To compare the clinical efficacy of pharmacological treatments for patients with an acute psychotic depression: antidepressant monotherapy, antipsychotic monotherapy, mifepristone monotherapy, and the combination of an antidepressant plus an antipsychotic versus placebo and/or each other. </p> <p>2. To assess whether differences in response to treatment in the current episode are related to non‐response to prior treatment. </p> </section> <section id="CD004044-sec-0003"> <h3 class="title" id="CD004044-sec-0003">Search methods</h3> <p>A search of the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR); Ovid MEDLINE (1950‐); Embase (1974‐); and PsycINFO (1960‐) was conducted on 21 February 2020. Reference lists of all included studies and related reviews were screened and key study authors contacted. </p> </section> <section id="CD004044-sec-0004"> <h3 class="title" id="CD004044-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) that included participants with acute major depression with psychotic features, as well as RCTs consisting of participants with acute major depression with or without psychotic features, that reported separately on the subgroup of participants with psychotic features. </p> </section> <section id="CD004044-sec-0005"> <h3 class="title" id="CD004044-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed risk of bias in the included studies, according to criteria from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. Data were entered into RevMan 5.1. We used intention‐to‐treat data. Primary outcomes were clinical response for efficacy and overall dropout rate for harm/tolerance. Secondary outcome were remission of depression, change from baseline severity score, quality of life, and dropout rate due to adverse effects. </p> <p>For dichotomous efficacy outcomes (i.e. response and overall dropout), risk ratios (RRs) with 95% confidence intervals (CIs) were calculated.  </p> <p>Regarding the primary outcome of harm, only overall dropout rates were available for all studies. If the study did not report any of the response criteria as defined above, remission as defined here could be used as an alternative. For continuously distributed outcomes, it was not possible to extract data from the RCTs.  </p> </section> <section id="CD004044-sec-0006"> <h3 class="title" id="CD004044-sec-0006">Main results</h3> <p>The search identified 3947 abstracts, but only 12 RCTs with a total of 929 participants could be included in the review. Because of clinical heterogeneity, few meta‐analyses were possible. The main outcome was reduction in severity (response) of depression, not of psychosis. </p> <p>For depression response, we found no evidence of a difference between antidepressant and placebo (RR 8.40, 95% CI 0.50 to 142.27; participants = 27, studies = 1; very low‐certainty evidence) or between antipsychotic and placebo (RR 1.13, 95% CI 0.74 to 1.73; participants = 201, studies = 2; very low‐certainty evidence). Furthermore, we found no evidence of a difference in overall dropouts with antidepressant (RR 1.24, 95% CI 0.34 to 4.51; participants = 27, studies = 1; very low‐certainty evidence) or antipsychotic monotherapy (RR 0.79, 95% CI 0.57 to 1.08; participants = 201, studies = 2; very low‐certainty evidence). </p> <p>No evidence suggests a difference in depression response (RR 2.09, 95% CI 0.64 to 6.82; participants = 36, studies = 1; very low‐certainty evidence) or overall dropouts (RR 1.79, 95% CI 0.18 to 18.02; participants = 36, studies = 1; very low‐certainty evidence) between antidepressant and antipsychotic. </p> <p>For depression response, low‐ to very low‐certainty evidence suggests that the combination of an antidepressant plus an antipsychotic may be more effective than antipsychotic monotherapy (RR 1.83, 95% CI 1.40 to 2.38; participants = 447, studies = 4), more effective than antidepressant monotherapy (RR 1.42, 95% CI 1.11 to 1.80; participants = 245, studies = 5), and more effective than placebo (RR 1.86, 95% CI 1.23 to 2.82; participants = 148, studies = 2). Very low‐certainty evidence suggests no difference in overall dropouts between the combination of an antidepressant plus an antipsychotic versus antipsychotic monotherapy (RR 0.79, 95% CI 0.63 to 1.01; participants = 447, studies = 4), antidepressant monotherapy (RR 0.91, 95% CI 0.55 to 1.50; participants = 245, studies = 5), or placebo alone (RR 0.75, 95% CI 0.48 to 1.18; participants = 148, studies = 2). </p> <p>No study measured change in depression severity from baseline, quality of life, or dropouts due to adverse events. We found no RCTs with mifepristone that fulfilled our inclusion criteria. </p> <p>Risk of bias is considerable: we noted differences between studies with regards to diagnosis, uncertainties around randomisation and allocation concealment, treatment interventions (pharmacological differences between various antidepressants and antipsychotics), and outcome criteria. </p> </section> <section id="CD004044-sec-0007"> <h3 class="title" id="CD004044-sec-0007">Authors' conclusions</h3> <p>Psychotic depression is heavily under‐studied, limiting confidence in the conclusions drawn. Some evidence indicates that combination therapy with an antidepressant plus an antipsychotic is more effective than either treatment alone or placebo. Evidence is limited for treatment with an antidepressant alone or with an antipsychotic alone. Evidence for efficacy of mifepristone is lacking. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004044-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004044-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004044-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004044-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004044-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004044-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004044-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004044-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004044-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004044-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004044-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004044-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004044-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004044-abs-0002" lang="en"> <h3>Pharmacological treatment for psychotic depression</h3> <p>Psychotic depression is a severe depression with psychotic features (i.e. delusions and/or hallucinations). Uncertainty surrounds the most effective drug treatment for psychotic depression: an antidepressant alone, an antipsychotic alone, or the combination of an antidepressant plus an antipsychotic. </p> <p>The aim of this review is to compare the efficacy of the various forms of drug treatment that have been used to treat psychotic depression. We did this by analysing all randomised controlled trials (RCTs). Twelve RCTs met our inclusion criteria. These trials involved a total of 929 people. </p> <p>From these trials, we found evidence that the combination of an antidepressant plus an antipsychotic provides more effective treatment for psychotic depression than either treatment alone. However, our confidence in this conclusion is limited because the information came from only a small number of RCTs, which included small numbers of people. In addition, the types of people involved varied between RCTs, and these trials differed in design, which means that we cannot confidently generalise their findings. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004044-sec-0137" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004044-sec-0137"></div> <h3 class="title" id="CD004044-sec-0138">Implications for practice</h3> <section id="CD004044-sec-0138"> <p>Psychotic depression is heavily under‐studied, limiting confidence in the conclusions drawn. Evidence suggests that combination therapy with an antidepressant plus an antipsychotic is more effective than either treatment alone or placebo. Evidence for treatment with an antidepressant alone or with an antipsychotic alone is lacking. </p> </section> <h3 class="title" id="CD004044-sec-0139">Implications for research</h3> <section id="CD004044-sec-0139"> <p>Further studies are needed:</p> <p> <ol id="CD004044-list-0014"> <li> <p>to study the efficacy of other combinations of an antidepressant plus an antipsychotic. Regarding antidepressants: combinations with a TCA, with a selective serotonin reuptake inhibitor (SSRI), with a serotonin‐noradrenaline reuptake inhibitor (SNRI), or with other (newer) antidepressants such as mirtazapine; regarding antipsychotics: combinations with other so called atypical antipsychotics (aripiprazole, risperidone, olanzapine, etc.); </p> </li> <li> <p>to compare the effects of the combination of an antidepressant with antipsychotics versus other pharmacological options, such as augmentation of an antidepressant with lithium or more experimental treatments such as ketamine and mifepristone; </p> </li> <li> <p>to compare the effects of the combination of an antidepressant plus an antipsychotic versus ECT; and </p> </li> <li> <p>to evaluate the efficacy of stepwise approaches or algorithms encompassing the previous steps after each other. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004044-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004044-sec-0008"></div> <div class="table" id="CD004044-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antidepressant compared to placebo for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant compared to placebo for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 8.40<br/>(0.50 to 142.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study defined depression response as HRSD‐17 &lt; 7</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/>(18 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.24<br/>(0.34 to 4.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000<br/>(78 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antipsychotic compared to placebo for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antipsychotic compared to placebo for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> at least first week of study in hospital<br/><b>Intervention:</b> antipsychotic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(0.74 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Studies defined depression response as reduction in HAMD‐24 ≥ 50% at endpoint</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>316 per 1000<br/>(207 to 484) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/>(0.57 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000<br/>(268 to 508) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antidepressant compared to antidepressant for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant compared to antidepressant for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant<br/><b>Comparison:</b> antidepressant </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical response</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not possible due to heterogeneity between the different antidepressants used </p> <p><a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> showed that imipramine may be more effective than fluvoxamine (RR 2.10, 95% CI 1.06 to 4.17) </p> <p><a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> showed that imipramine may be more effective than mirtazapine (RR 3.00, 95% CI 1.01 to 8.95) </p> <p><a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> showed that sertraline may be more effective than paroxetine (RR 3.37, 95% CI 1.19 to 9.57) </p> <p><a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a> found no difference between fluvoxamine and venlafaxine (RR 1.50, 95% CI 0.82 to 2.75) </p> <p><a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> found no difference between imipramine and venlafaxine (RR 1.57, 95% CI 0.93 to 2.67) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> found no difference between imipramine and venlafaxine (RR 0.81, 95% CI 0.33 to 2.03) </p> <p><a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> found no difference between imipramine and mirtazapine (RR 0.50, 95% CI 0.19 to 1.31) </p> <p><a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> found no difference between imipramine and fluvoxamine (RR 2.00, 95% CI 0.40 to 9.95) </p> <p><a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> found no difference between sertraline and paroxetine (RR 0.20, 95% CI 0.01 to 3.74) </p> <p><a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a> found no difference between fluvoxamine and venlafaxine (RR 0.07, 95% CI 0.00 to 1.20) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>b</sup>Downgraded one level for imprecision as CIs are consistent with appreciable benefit and appreciable harm. </p> <p><sup>c</sup>Downgraded one level for high risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antidepressant compared to antipsychotic for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant compared to antipsychotic for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant<br/><b>Comparison:</b> antipsychotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antipsychotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.09<br/>(0.64 to 6.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study defined depression response as HRSD‐17 &lt; 7</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>369 per 1000<br/>(113 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.79<br/>(0.18 to 18.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/>(11 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>b</sup>Downgraded one level for imprecision as CIs are consistent with appreciable benefit and appreciable harm. </p> <p><sup>c</sup>Downgraded one level for risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> at least first week of study in hospital<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.86<br/>(1.23 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Both studies defined response as reduction in HAMD‐24 ≥ 50% at endpoint</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000<br/>(344 to 790) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.48 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000<br/>(226 to 555) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for for high risk of other source of bias. </p> <p><sup>b</sup>Downgraded one level for for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>d</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus antipsychotic for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo plus antipsychotic for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital (2 RCTs) or at least first week of study in hospital (2 RCTs)<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo plus antipsychotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus antipsychotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.83<br/>(1.40 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>447<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies defined response as reduction in HAMD‐24 ≥ 50% at endpoint, 1 study defined response as HAMD‐17 ≦ 10, and another study defined response as HRSD‐17 &lt; 7 </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>487 per 1000<br/>(373 to 633) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/>(0.63 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>447<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 per 1000<br/>(274 to 440) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Depression Rating Scale; <b>HRSD:</b> Hamilton Rating Scale for Depression; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other source of bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision as CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus antidepressant for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo plus antidepressant for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo plus antidepressant </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus antidepressant</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.42<br/>(1.11 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>245<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One study defined response as HRSD‐17 &lt; 7, another study defined response as HAMD‐17 ≦ 10, another study defined response as HAMD‐17 &lt; 11, and a fourth study defined response as reduction in HRSD‐17 &gt; 50% </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>436 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>619 per 1000<br/>(484 to 784) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.55 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>245<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1,000<br/>(114 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Depression Rating Scale; <b>HRSD:</b> Hamilton Rating Scale for Depression; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for high risk of attrition bias and other source of bias in one study. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>d</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004044-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus the same antidepressant for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo plus the same antidepressant for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo plus the same antidepressant </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus the same antidepressant</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70<br/>(1.19 to 2.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One study defined response as HAMD‐17 &lt; 11, another study defined response as HRSD‐17 &lt; 7, and a third study defined response as ≧ 50% decrease in HAMD‐17 scores from baseline to study endpoint </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>596 per 1000<br/>(417 to 852) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.52 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000<br/>(88 to 349) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Depression Rating Scale; <b>HRSD:</b> Hamilton Rating Scale for Depression; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other source of bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>d</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable harm and appreciable benefit. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004044-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004044-sec-0009"></div> <section id="CD004044-sec-0010"> <h3 class="title" id="CD004044-sec-0010">Description of the condition</h3> <p>Psychotic depression is a severe condition that is defined as a depressive episode with psychotic features (i.e. delusions and/or hallucinations) in the context of a (unipolar) major depressive disorder. Psychotic depression is not uncommon. In the US Epidemiologic Catchment Area Study (<a href="./references#CD004044-bbs2-0049" title="JohnsonJ , HorwathE , WeismanMM . The validity of major depression with psychotic features based on a community study. Archives of General Psychiatry1991;48(12):1075-81.">Johnson 1991</a>), 14% of participants who met the criteria for major depression had a history of episodes with psychotic features. In a European general population study, 18.5% of respondents with a major depressive episode had psychotic features; the prevalence of psychotic depression was 0.4%, and of non‐psychotic depression 2.0% (<a href="./references#CD004044-bbs2-0057" title="OhayonMM , SchatzbergAF . Prevalence of depressive episodes with psychotic features in the general population. American Journal of Psychiatry2002;159(11):1855-61.">Ohayon 2002</a>). In a US study of hospitalised patients with major depression, 25% met the criteria for psychotic depression (<a href="./references#CD004044-bbs2-0040" title="CoryellW , PfohlB , ZimmermanM . The clinical and neuroendocrine features of psychotic depression. Journal of Nervous and Mental Disease1984;172(9):521-8.">Coryell 1984</a>). Compared with non‐psychotic depression, psychotic depression is marked by greater severity, increased incapacity, decreased likelihood of placebo response, longer duration of episodes, and recurrence of psychotic features in subsequent episodes (<a href="./references#CD004044-bbs2-0041" title="CoryellW . The treatment of psychotic depression. Journal of Clinical Psychiatry1998;59(Suppl 1):22-9.">Coryell 1998</a>). </p> </section> <section id="CD004044-sec-0011"> <h3 class="title" id="CD004044-sec-0011">Description of the intervention</h3> <p>Guidelines recommend electroconvulsive therapy (ECT) or pharmacotherapy as treatment for psychotic depression (<a href="./references#CD004044-bbs2-0038" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Washington, DC: American Psychiatric Association, 2010.">APA 2010</a>; <a href="./references#CD004044-bbs2-0056" title="National Institute for Health and Clinical Excellence. The treatment and management of depression in adults (updated version). National Clinical Practice Guideline 90. London: HMSO, 2009.">NICE 2009</a>). Pharmacotherapy for psychotic depression could consist of an antipsychotic, an antidepressant, or a combination of both. Most guidelines recommend treatment that combines an antidepressant with an antipsychotic (<a href="./references#CD004044-bbs2-0038" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Washington, DC: American Psychiatric Association, 2010.">APA 2010</a>; <a href="./references#CD004044-bbs2-0056" title="National Institute for Health and Clinical Excellence. The treatment and management of depression in adults (updated version). National Clinical Practice Guideline 90. London: HMSO, 2009.">NICE 2009</a>). However, discussion continues regarding whether the combination of an antipsychotic plus an antidepressant is more effective than monotherapy with an antidepressant or an antipsychotic  (<a href="./references#CD004044-bbs2-0052" title="MahliGS , AdamsD , PorterR , WignallA , LampeL , O'ConnorN , et al. Clinical practice recommendations for depression. Acta Psychiatrica Scandinavica2009;119:8-26.">Mahli 2009</a>; <a href="./references#CD004044-bbs2-0054" title="SpijkerJ , BocktingCLH , MeeuwissenJAC , Vliet IM van, EmmelkampPMG , HermensMLM , et al (van namens de Werkgroep Multidisciplinaire richtlijnontwikkeling Angststoornissen/Depressie). Multidisciplinaire richtlijn Depressie (Derde revisie). Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis; 2013. Utrecht: Trimbos Institute. Available at www.nvvp.net/stream/richtlijn-depressie-2013.pdf.">Multidisciplinaire Richtlijn Depressie 2013</a>; <a href="./references#CD004044-bbs2-0058" title="ParkerG , RoyK , Hadzi-PavlovicD , PedicF . Psychotic (delusional) depression: a meta-analysis of physical treatments. Journal of Affective Disorders1992;24(1):17-24.">Parker 1992</a>; <a href="./references#CD004044-bbs2-0069" title="WijkstraJ , LijmerJ , BalkF , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub2]">Wijkstra 2005</a>; <a href="./references#CD004044-bbs2-0067" title="WijkstraJ , SchubartCD , NolenWA . Treatment of unipolar psychotic depression: the use of evidence in practice guideline. World Journal of Biological Psychiatry2007;24:1-7.">Wijkstra 2007</a>). The intervention studied in this review is pharmacological treatment for psychotic depression, including the question of whether the combination of an antipsychotic plus an antidepressant is more effective than either treatment given as monotherapy. </p> </section> <section id="CD004044-sec-0012"> <h3 class="title" id="CD004044-sec-0012">How the intervention might work</h3> <p>All antidepressants enhance the activity of serotonin and/or noradrenaline, and some of them (also) dopamine (<a href="./references#CD004044-bbs2-0063" title="SadockJ , SadockVA , Ruiz P (editors). Comrehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). Most antidepressants achieve this via inhibition of reuptake of these neurotransmitters in the presynaptic neuron (tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin‐noradrenaline reuptake inhibitors (SNRIs)), although some antidepressants have other working mechanisms (e.g. blockade of postsynaptic serotonin‐2 receptors such as mirtazapine, inhibition of their breakdown via inhibition of the enzyme monoamine oxidase (MAOI)). Nevertheless, their noradrenergic and serotonergic effects do not completely explain their efficacy, as these effects occur already within hours after first intake, but it takes days to weeks before antidepressants begin to exert their effects in patients with depression or anxiety (<a href="./references#CD004044-bbs2-0063" title="SadockJ , SadockVA , Ruiz P (editors). Comrehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). </p> <p>Almost all antipsychotics (classical as well as atypical antipsychotics, with the exception of clozapine) are blockers of the postsynaptic dopamine‐2 receptor, and their therapeutic efficacy is correlated with their affinity for dopamine‐2 receptors in vivo. However, other effects may contribute to their efficacy, such as their affinity for presynaptic serotonin‐1 receptors, postsynaptic serotonin‐2 receptors, and histamine receptors, as can be seen with some atypical antipsychotics (e.g. olanzapine, quetiapine). Similar to antidepressants, these effects do not completely explain their efficacy because they also occur already within hours after first intake, but it takes days to weeks for antipsychotics to begin to work (<a href="./references#CD004044-bbs2-0063" title="SadockJ , SadockVA , Ruiz P (editors). Comrehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). </p> <p>The traditional view is that antidepressants work against depression and antipsychotics work against psychosis. Therefore, it seems appropriate in psychotic depression to treat the psychotic symptoms with an antipsychotic and the depressive symptoms with an antidepressant. However, when psychotic depression is considered as the most severe form of depression, and when psychosis is viewed as the distal consequence of that severity (as is the case in the <i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM‐IV‐TR),</i> <a href="./references#CD004044-bbs2-0037" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000.">APA 2000</a>, and Fifth Edition (DSM‐5), <a href="./references#CD004044-bbs2-0039" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th edition. Washington, DC: American Psychiatric Association, 2013.">APA 2013</a>)), treatment with an antidepressant alone seems logical. On the other hand, treatment with an antipsychotic alone, especially one of the newer atypical antipsychotics with possible antidepressant effects, cannot be ruled out. </p> <p>Other studies suggest that dysregulation of the hypothalamic‐pituitary‐adrenal axis found in patients with psychotic depression might be a biologically targeted treatment opportunity (<a href="./references#CD004044-bbs2-0042" title="DuvalF , MokraniMC , Monreal-OrtizJA , FattahS , ChampevalC , SchulzP , et al. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology2006;31(7):876-88.">Duval 2006</a>), as abnormalities in the diurnal fluctuation of cortisol have been found (<a href="./references#CD004044-bbs2-0050" title="KellerJ , FloresB , GomezRG , SolvasonHB , KennaH , WilliamsGH , et al. Cortisol circadian rhythm alterations in psychotic major depression. Biological Psychiatry2006;60(3):275-81.">Keller 2006</a>), and high rates of non‐suppression on the dexamethasone suppression test have been observed (<a href="./references#CD004044-bbs2-0055" title="NelsonJC , DavisJM . DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry1997;154(11):1497-503.">Nelson 1997</a>). Therefore, the glucocortoid receptor antagonist mifepristone has been proposed as a possible pharmacological treatment for psychotic depression (<a href="./references#CD004044-bbs2-0013" title="BelanoffJK , FloresBH , KalezhanM , SundB , SchatzbergAF . Rapid reversal of psychotic depression using mifepristone. Journal of Clinical Psychopharmacology2001;21(5):516-21. ">Belanoff 2001</a>).  </p> </section> <section id="CD004044-sec-0013"> <h3 class="title" id="CD004044-sec-0013">Why it is important to do this review</h3> <p>Clinical practice is characterised by uncertainty as to whether it is most appropriate to start treatment in this patient group with antidepressant monotherapy or with the combination of an antidepressant and an antipsychotic because of potential adverse effects of antipsychotics (especially extrapyramidal side effects, hyperprolactinaemia, and risk of metabolic syndrome, including weight gain). A previous meta‐analysis did not find a statistically significant difference between TCA monotherapy and combination therapy (<a href="./references#CD004044-bbs2-0058" title="ParkerG , RoyK , Hadzi-PavlovicD , PedicF . Psychotic (delusional) depression: a meta-analysis of physical treatments. Journal of Affective Disorders1992;24(1):17-24.">Parker 1992</a>). However, the findings and conclusions of that meta‐analysis were limited by inadequate methods of many included studies, which were often retrospective, uncontrolled, and/or not randomised. Some international guidelines on the pharmacological treatment of psychotic depression (in the United States ‐ <a href="./references#CD004044-bbs2-0055" title="NelsonJC , DavisJM . DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry1997;154(11):1497-503.">Nelson 1997</a>; in the Netherlands ‐ <a href="./references#CD004044-bbs2-0054" title="SpijkerJ , BocktingCLH , MeeuwissenJAC , Vliet IM van, EmmelkampPMG , HermensMLM , et al (van namens de Werkgroep Multidisciplinaire richtlijnontwikkeling Angststoornissen/Depressie). Multidisciplinaire richtlijn Depressie (Derde revisie). Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis; 2013. Utrecht: Trimbos Institute. Available at www.nvvp.net/stream/richtlijn-depressie-2013.pdf.">Multidisciplinaire Richtlijn Depressie 2013</a>) and those presented in reviews ‐ <a href="./references#CD004044-bbs2-0066" title="Wheeler VegaJA , MortimerAM , TysonPJ . Somatic treatment of psychotic depression: review and recommendations for practice. Journal of Clinical Psychopharmacology2000;20(5):504-19.">Wheeler 2000</a> ‐ suggest that one may consider TCA monotherapy before adding an antipsychotic. However, in contrast, the American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depressive Disorder and the National Institute for Health and Clinical Excellence recommend initial combination therapy (<a href="./references#CD004044-bbs2-0038" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Washington, DC: American Psychiatric Association, 2010.">APA 2010</a>; <a href="./references#CD004044-bbs2-0056" title="National Institute for Health and Clinical Excellence. The treatment and management of depression in adults (updated version). National Clinical Practice Guideline 90. London: HMSO, 2009.">NICE 2009</a>). The same recommendation is made in the <a href="./references#CD004044-bbs2-0041" title="CoryellW . The treatment of psychotic depression. Journal of Clinical Psychiatry1998;59(Suppl 1):22-9.">Coryell 1998</a> review. This variation between guidelines reflects the limited evidence on which these guidelines are based. In a review about evidence used in practice guidelines (<a href="./references#CD004044-bbs2-0067" title="WijkstraJ , SchubartCD , NolenWA . Treatment of unipolar psychotic depression: the use of evidence in practice guideline. World Journal of Biological Psychiatry2007;24:1-7.">Wijkstra 2007</a>), we concluded that physicians (and patients) should be aware that guidelines for treatment recommendations may be less evidence‐based than asserted, even when it is stated that treatment recommendations are based on the highest level of evidence. </p> <p>Treatment with a classical antipsychotic alone is not recommended, primarily because of findings reported by <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>, in which treatment with perphenazine alone was less effective than treatment with perphenazine plus amitriptyline. However, atypical antipsychotics may be worth reconsidering now because of reduced risk of extrapyramidal side effects and potential antidepressant properties associated with some of these agents (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>). </p> <p>This review is an update of our Cochrane Review first published in 2005 and updated in 2015 (<a href="./references#CD004044-bbs2-0069" title="WijkstraJ , LijmerJ , BalkF , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub2]">Wijkstra 2005</a>; <a href="./references#CD004044-bbs2-0071" title="WijkstraJ , LijmerJ , BurgerH , CiprianiA , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub4]">Wijkstra 2015</a>). The conclusion in 2015 was as follows: “psychotic depression is heavily understudied, limiting confidence in the conclusions drawn. Some evidence indicates that combination therapy with an antidepressant plus an antipsychotic is more effective than either treatment alone or placebo. Evidence is limited for treatment with an antidepressant alone or with an antipsychotic alone”. </p> <p>Since 2015, a few more studies may have been conducted that might lead to a different conclusion regarding treatment with an antidepressant alone or with the combination of an antidepressant and an antipsychotic, as well as with other psychopharmacological agents, such as mifepristone. </p> <p>Another important clinical issue is that differences in response to specific treatments may be explained in relation to non‐response to prior treatment(s). In generalising from observations across medical disciplines, it would be expected that patients who did not respond to adequate treatment would respond less to subsequent treatment. Some data are available on this topic with regard to pharmacological treatment of major depressive disorder (<a href="./references#CD004044-bbs2-0062" title="SackeimHA . The definition and meaning of treatment-resistant depression. Journal of Clinical Psychiatry2001;62(Suppl 16):10-7.">Sackeim 2001</a>). Two studies showed that a greater degree of treatment resistance predicts an inferior response to ECT (<a href="./references#CD004044-bbs2-0059" title="PrudicJ , SackeimHA , DevanandDP . Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Research1990;31(3):287-96.">Prudic 1990</a>; <a href="./references#CD004044-bbs2-0060" title="PrudicJ , HaskettRF , MulsantB , MaloneKM , PettinatiHM , StephensS , et al. Resistance to antidepressant medications and short-term clinical response to ECT. American Journal of Psychiatry1996;153(8):985-92.">Prudic 1996</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004044-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004044-sec-0014"></div> <p> <ol id="CD004044-list-0001"> <li> <p>To compare the clinical efficacy of pharmacological treatments for patients with an acute psychotic depression: antidepressant monotherapy, antipsychotic monotherapy, mifepristone monotherapy, and the combination of an antidepressant plus an antipsychotic versus placebo and/or each other </p> </li> <li> <p>To assess whether differences in response to treatment in the current episode are related to non‐response to prior treatment </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004044-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004044-sec-0015"></div> <section id="CD004044-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004044-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing pharmacological treatments for patients with acute psychotic depression. </p> <p>As we expected to identify very few RCTs assessing treatment of psychotic depression as the primary focus, we decided a priori to also include RCTs assessing treatment of major depression with or without psychotic features. Effects in the subgroup of participants with psychotic features should then be reported separately, irrespective of whether the subgroup with psychotic features was stratified before randomisation. </p> <p>We applied no language restrictions for included studies.</p> </section> <section id="CD004044-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants of any age in any setting (both inpatients and outpatients) had a major depressive disorder and a current episode with psychotic features (delusions and/or hallucinations appearing in the context of a full major depressive episode) according to the <i>Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM‐III)/DSM, Third Edition, Revised (DSM‐III‐R)/DSM, Fourth Edition (DSM‐IV)/DSM, Fourth Edition, Text Revision (DSM‐IV‐TR), Fifth Edition (DSM‐5)</i> (<a href="./references#CD004044-bbs2-0034" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington, DC: American Psychiatric Association, 1980.">APA 1980</a>; <a href="./references#CD004044-bbs2-0035" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edition, revised. Washington, DC: American Psychiatric Association, 1987.">APA 1987</a>; <a href="./references#CD004044-bbs2-0036" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington, DC: American Psychiatric Association, 1994.">APA 1994</a>; <a href="./references#CD004044-bbs2-0037" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000.">APA 2000</a>; <a href="./references#CD004044-bbs2-0039" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th edition. Washington, DC: American Psychiatric Association, 2013.">APA 2013</a>), or consistent with <i>International Classification of Diseases (ICD)</i> codes for the same. </p> <p>We also included studies in which participants had comorbidities, as comorbidity was not a reason for exclusion. </p> <p>As patients with a major depressive episode in the context of a bipolar disorder (bipolar depression) are at increased risk of switching to mania (<a href="./references#CD004044-bbs2-0051" title="LichtRW , GijsmanH , NolenWA , AngstJ . Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatrica Scandinavica2008;118(5):337-46.">Licht 2008</a>), we intended to include only trials that assessed participants with unipolar depression. If trials had included participants with both unipolar and bipolar depression, we decided a priori to include only trials for which results in the unipolar group were reported separately, or for which the percentage of participants with bipolar depression did not exceed 20% of the total study population. </p> </section> <section id="CD004044-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included any pharmacological treatment of a current (i.e. acute) episode. Treatment had to be given for at least four weeks with the intention of treating the current episode. </p> <p>When possible, we considered the following pair‐wise comparisons.</p> <p> <ol id="CD004044-list-0002"> <li> <p>Antidepressant versus placebo.</p> </li> <li> <p>Antipsychotic versus placebo.</p> </li> <li> <p>Antidepressant versus antidepressant.</p> </li> <li> <p>Antipsychotic versus antipsychotic.</p> </li> <li> <p>Antidepressant versus antipsychotic.</p> </li> <li> <p>Antidepressant plus antipsychotic versus placebo.</p> </li> <li> <p>Antidepressant plus antipsychotic versus placebo plus antidepressant.</p> </li> <li> <p>Antidepressant plus antipsychotic versus placebo plus antipsychotic.</p> </li> <li> <p>Mifepristone versus placebo.</p> </li> <li> <p>Mifepristone plus antidepressant versus placebo plus antidepressant.</p> </li> <li> <p>Other psychopharmacological agents versus placebo.</p> </li> <li> <p>Other psychopharmacological agents plus antidepressant versus placebo plus antidepressant.</p> </li> </ol> </p> </section> <section id="CD004044-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004044-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004044-list-0003"> <li> <p>Efficacy: clinical response of depression based on observer‐rated symptom reduction: reduction of at least 50% on the Hamilton Rating Scale for Depression (HRSD; <a href="./references#CD004044-bbs2-0046" title="HamiltonM . A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry1960;23:56-62.">Hamilton 1960</a>), the Montgomery Åsberg Depression Rating Scale (MADRS; <a href="./references#CD004044-bbs2-0053" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382-9.">Montgomery 1979</a>), or any other observer depression severity rating scale, or a change score on the Clinical Global Impression‐Change (CGI‐C) of 'much improved' or 'very much improved' (<a href="./references#CD004044-bbs2-0045" title="GuyW . Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health,1976.">Guy 1976</a>)  </p> </li> <li> <p>Harm: overall dropout rate during acute treatment as a proxy measure of overall acceptability of treatment </p> </li> </ol> </p> </section> <section id="CD004044-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004044-list-0004"> <li> <p>Remission of depression as defined in reports and based on HRSD or MADRS or other observer depression severity rating scale. If the study did not report any of the response criteria as defined above, remission as defined here may be used as an alternative </p> </li> <li> <p>Change from baseline in score on HRSD, MADRS, or any other observer depression severity rating scale, or change in severity on CGI‐C </p> </li> <li> <p>Quality of life, as defined in reports</p> </li> <li> <p>Dropout rate due to adverse effects</p> </li> </ol> </p> </section> </section> </section> <section id="CD004044-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004044-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Search strategies were updated from 2013 onwards. </p> <p>Previous searches, conducted up to April 2013, for earlier versions of this review ‐ <a href="./references#CD004044-bbs2-0069" title="WijkstraJ , LijmerJ , BalkF , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub2]">Wijkstra 2005</a> and <a href="./references#CD004044-bbs2-0071" title="WijkstraJ , LijmerJ , BurgerH , CiprianiA , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub4]">Wijkstra 2015</a> ‐ can be found in <a href="https://revman.cochrane.org/396497034347841393" target="_blank">Appendix X</a>, with a description of the Cochrane Common Mental Disorders Group (CCMD) controlled trials register (CCMDCTR) provided in <a href="https://revman.cochrane.org/414806368778583540" target="_blank">Appendix X</a>. </p> <p>For this update of this review, the CCDANCTR Studies Register was searched (from 2013 to 12 February 2020) using the following terms. </p> <p>Condition = (depressi* or “affective disorder*” or “affective symptoms”) </p> <p>AND </p> <p>Condition or Comorbidity = (psychosis or psychoses or psychotic* or delusion*)</p> <p>The CCDANCTR Studies Register was searched (all years to 12 April 2013) using the following terms to identify additional untagged references. </p> <p>Title/Abstract/Keywords = ((depressi* or “affective disorder*” or “affective symptoms”) </p> <p>AND</p> <p>Free‐Text = (psychosis or psychoses or psychotic* or delusion* or hallucin* or antipsychotic* or psychotropic*)) </p> <p>An information specialist with CCMD (previously known as the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDAN)) ran an updated search (21 February 2020) of the following electronic databases, using relevant subject headings (controlled vocabularies) and search syntax, as appropriate to each resource.  </p> <p> <ol id="CD004044-list-0005"> <li> <p>Ovid MEDLINE.</p> </li> <li> <p>Ovid Embase.</p> </li> <li> <p>Ovid PsycINFO.</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; February 2020, Issue 2 of 12). </p> </li> <li> <p>Cochrane Common Mental Disorders Controlled Trials Register (CMDCTR).</p> </li> </ol> </p> <p>The international trial registries (ClinicalTrials.gov and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)) were searched via CENTRAL, in the Cochrane Library (all years from 2013 to 12 February 2020). </p> <p>We applied no restrictions on language or publication status to these searches.</p> </section> <section id="CD004044-sec-0025"> <h4 class="title">Searching other resources</h4> <p>The reference lists of all studies, related reviews, and relevant conference proceedings were screened, and key study authors contacted. </p> </section> </section> <section id="CD004044-sec-0026"> <h3 class="title" id="CD004044-sec-0026">Data collection and analysis</h3> <section id="CD004044-sec-0027"> <h4 class="title">Selection of studies</h4> <p>In step 1, all abstracts of identified publications were screened independently by two review authors (JL and JW in 2005 and 2015, JK and EL in 2020), and studies were selected if they met the following criteria. </p> <p> <ol id="CD004044-list-0006"> <li> <p>Were randomised controlled trial (RCT).</p> </li> <li> <p>Included participants with a major depressive disorder.</p> </li> <li> <p>Investigated the efficacy of pharmacological treatment.</p> </li> <li> <p>Focused on acute phase treatment (minimum of four weeks' treatment), not on continuation or maintenance treatment. </p> </li> </ol> </p> <p>If any doubt or disagreement arose between the review authors, the publication was included in step 2. Full articles were obtained for the selected abstracts. </p> <p>In step 2, selected full articles were screened (JL and JW in 2005 and 2015, JK and EL in 2020) according to the following criteria. </p> <p> <ol id="CD004044-list-0007"> <li> <p>Participants with psychotic depression were not excluded.</p> </li> <li> <p>Results in the subgroup of psychotic depressed participants were reported separately.</p> </li> </ol> </p> <p>If any doubt arose about an article, it was included in step 4.</p> <p>In step 3, the reference lists of related reviews and of included publications, conference abstracts, and personal communications were searched. </p> <p>Finally, in step 4, two review authors (JL and JW in 2005 and 2015, JK and EL in 2020) independently reviewed all identified publications according to the full inclusion criteria of the review. Any disagreement was resolved by consensus discussion with another review author (WN). </p> </section> <section id="CD004044-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Extracted data included the following: participant characteristics (age, gender, setting: inpatient/outpatient); diagnosis (diagnostic instrument, system of classification, number of bipolar participants); prior treatment for the current episode; intervention; length of illness; suicide attempts; treatment details (treatment period, washout period, additional medication, blood levels, doses); and outcome measures. Data were extracted independently by two review authors (JL and JW in 2005 and 2015; JK and EL in 2020). </p> <p>All data (from the 2013 review and recent data) were entered into RevMan 5.4 (<a href="./references#CD004044-bbs2-0061" title="Review Manager 5 (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2020</a>). </p> </section> <section id="CD004044-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In the original version of this review, we assessed methodological quality of included studies using criteria set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004044-bbs2-0033" title="AldersonP , GreenS , HigginsJPT . Cochrane Reviewer's Handbook 4.2.2. Chichester: John Wiley &amp; Sons, Ltd, 2004.">Alderson 2004</a>); however, after publication of the revised and expanded <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004044-bbs2-0047" title="HigginsJT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), we updated our methods accordingly. Working independently, two review authors (JL and JW in 2005 and 2015; JK and EL in 2020) assessed risk of bias of included studies using the tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004044-bbs2-0048" title="HigginsJT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8. Assessing risk of bias in a randomized trial. In: Higgins JT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>). The following items were assessed. </p> <p> <ol id="CD004044-list-0008"> <li> <p>Sequence generation: was the allocation sequence adequately generated?</p> </li> <li> <p>Allocation concealment: was allocation adequately concealed?</p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors for each main outcome or class of outcomes: was knowledge of the allocated treatment adequately prevented during the study? </p> </li> <li> <p>Incomplete outcome data for each main outcome or class of outcomes: were incomplete outcome data adequately addressed? </p> </li> <li> <p>Selective outcome reporting: were reports of the study free of suggestion of selective outcome reporting? </p> </li> <li> <p>Other sources of bias: was the study apparently free of other problems that could put it at high risk of bias? </p> </li> </ol> </p> <p>We included quotations from the text of included studies and comments on how we assessed risk of bias; we judged each study to be at low, unclear, or high risk of bias. </p> <p>See risk of bias figures (<a href="#CD004044-fig-0001">Figure 1</a>; <a href="#CD004044-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD004044-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004044-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004044-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004044-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>If disputes arose as to which judgement should be given, resolution was achieved after consultation with the third review author (WN). </p> </section> <section id="CD004044-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004044-sec-0031"> <h5 class="title">Binary outcomes</h5> <p>For binary efficacy outcomes, such as response, remission, and dropouts, we calculated the risk ratio (RR) (with 95% confidence intervals (CI)) for each comparison using numbers randomly assigned and numbers of events. </p> </section> <section id="CD004044-sec-0032"> <h5 class="title">Continuous outcomes</h5> <p>For continuously distributed outcomes, we calculated the standardised mean difference (SMD). </p> <p>We presented skewed and non‐quantitative outcome data descriptively.</p> </section> </section> <section id="CD004044-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We identified neither cluster‐randomised nor cross‐over trials. However, if found, we would not have included them in our review, as we were interested in differences not between clusters (e.g. clinics) but between drugs or classes of drugs; nor were we interested in the results of a cross‐over phase, as the outcome of the first phase might have had an impact on the outcome of the second (i.e. cross‐over) phase. </p> <p>In case a study had multiple intervention groups, we included only data for the pair‐wise comparison in question. Further, if a study compared two or more medications of the same type (e.g. venlafaxine, imipramine), we combined data into a single category, for example, the category 'antidepressant'. </p> </section> <section id="CD004044-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) response data in the analyses, as ITT data are less biased, and because they address a more pragmatic and clinically relevant question (<a href="./references#CD004044-bbs2-0047" title="HigginsJT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). When necessary, we converted response data from trials into ITT response data by using the total number of randomly assigned participants per group who had started with treatment as the denominator. So participants who had started with medication but were withdrawn before endpoint were assumed not to have experienced response. </p> <p>When data were missing, we contacted study authors to request the required data.</p> <p>We used no other imputation techniques to deal with missing data.</p> </section> <section id="CD004044-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>First, we evaluated whether clinical homogeneity could be assumed by evaluating any between‐study dissimilarities regarding participants, interventions, and outcome measures. We excluded from the meta‐analysis studies that were considered to threaten the clinical homogeneity assumption. </p> <p>We used the I² statistic supplied with a 95% CI to assess the magnitude of statistical heterogeneity when values exceeding 0.40 were considered possibly relevant. We did not perform the Q test to determine heterogeneity because of its low power in our meta‐analysis resulting from low numbers of studies in all of our comparisons. </p> <p>We planned to conduct re‐stated subgroup analyses to explore sources of heterogeneity. We performed no meta‐regression. </p> </section> <section id="CD004044-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>When data from at least 10 studies became available, we assessed the presence of publication bias by using contour‐enhanced funnel plots in which treatment effects expressed as RR (risk ratio) from individual studies were plotted against each study's sample size. We did not perform Egger's regression test in view of low statistical power in our meta‐analyses, again resulting from the low number of included studies. </p> <p>It must be noted that asymmetry of funnel plots does not necessarily indicate publication bias but may result from other biases such as inflated results in smaller studies due to poorer methodological quality, or true heterogeneity. </p> </section> <section id="CD004044-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We used the Mantel‐Haenszel fixed‐effect method to calculate pooled risk ratios with 95% confidence intervals. Risk ratios are preferred over odds ratios because of their more straightforward interpretation (i.e. the number of times the outcome is more likely to occur given one treatment over another). We used fixed‐effect models as most meta‐analyses consisted of a small number of studies, therefore there were insufficient data to estimate random‐effects models. </p> </section> <section id="CD004044-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient data were available, we planned to conduct the following subgroup analyses.</p> <p> <ol id="CD004044-list-0009"> <li> <p>Participants who were non‐refractory to prior treatment(s) during the current episode.</p> </li> <li> <p>Participants with mood congruent psychotic features only.</p> </li> </ol> </p> <p>Because all psychotically depressed patients are considered to be severely depressed, it was not considered appropriate to evaluate baseline severity in a subgroup analysis. </p> </section> <section id="CD004044-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>If sufficient data were available, we planned to perform the following sensitivity analyses. </p> <p> <ol id="CD004044-list-0010"> <li> <p>Studies focusing on psychotic depression only.</p> </li> <li> <p>Studies in which participants with psychotic depression were separately randomised.</p> </li> <li> <p>Studies of lower methodological quality to assess robustness of results.</p> </li> <li> <p>Smaller versus larger studies.</p> </li> </ol> </p> </section> <section id="CD004044-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p> We created 'Summary of findings' tables, in which we summarised findings of studies comparing: </p> <p> <ol id="CD004044-list-0011"> <li> <p>antidepressant versus placebo;</p> </li> <li> <p>antipsychotic versus placebo;</p> </li> <li> <p>antidepressant versus antidepressant;</p> </li> <li> <p>antipsychotic versus antipsychotic;</p> </li> <li> <p>antidepressant versus antipsychotic;</p> </li> <li> <p>antidepressant plus antipsychotic versus placebo;</p> </li> <li> <p>antidepressant plus antipsychotic versus placebo plus antidepressant; and</p> </li> <li> <p>antidepressant plus antipsychotic versus placebo plus antipsychotic.</p> </li> </ol> </p> <p>We have presented a separate 'Summary of findings' table for each comparison group. We included the following outcomes: depression response, overall dropout, depression remission, change in depression severity, quality of life, and dropout due to adverse effects as measured between baseline and end of study. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence as it relates to studies that contributed data to meta‐analyses for prespecified outcomes. We used methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004044-bbs2-0064" title="SchünemannHJ , HigginsJT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14. Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>), along with GRADEpro software (<a href="./references#CD004044-bbs2-0044" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime) (accessed prior to 3 March 2020). Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downgrade the certainty of evidence by using footnotes, and we made comments to aid the reader's understanding of the review when necessary. </p> <p>Two review authors (BV, LR) independently assessed the certainty of evidence and resolved disagreements through discussion or by consultation with a third review author (WN). We justified, documented, and incorporated judgements into reporting of results for each outcome. </p> <section id="CD004044-sec-0041"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice, and our implications for research suggest priorities for future research and outline what remaining uncertainties in this area of research. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004044-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004044-sec-0042"></div> <section id="CD004044-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD004044-sec-0044"> <h4 class="title">Results of the search</h4> <p>From the Cochrane Central Register of Controlled Trials (CENTRAL) search conducted in 2004, we identified 1782 publications: MEDLINE 720, Embase 831; total, 3333. With some overlap from 2004, we have since found an additional 326 publications. The first step of screening abstracts of these publications in 2004 resulted in 798 relevant publications (749 from CENTRAL, 38 from MEDLINE, 11 from Embase); in 2011, we found 40 additional studies (3 from CENTRAL, 32 from CCDANCTR‐References Register, 5 from CCDANCTR‐Studies Register). The second step of screening the full articles of these publications in 2004 resulted in identification of 52 publications (47, 3, and 2, respectively) and now 17 (1 from CENTRAL, 13 from CCDANCTR‐References Register, 3 from CCDANCTR‐Studies Register). In 2004, handsearching of reference lists from relevant reviews resulted in identification of one other publication (<a href="./references#CD004044-bbs2-0014" title="BelliniL , GasperiniM , GattiF , FranchiniL , SmeraldiE . A double blind study with fluvoxamine vs. desipramine combined with placebo or haloperidol in delusional depression. Critical Issues in the Treatment of Affective Disorders1994;9:32-6. ">Bellini 1994</a>), and handsearching of included publications did not lead to identification of any further relevant publications. Now, this resulted in no publications. In 2004, the final fourth step of reviewing these 53 publications resulted in 7 included studies, and in 2004, we added 2 other publications that we knew were in press: 1 by van den Broek (<a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>), and the other reporting 2 similar trials (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). Thus, in 2004 in total, we included nine publications with 10 RCTs. Now, in the fourth step, by reviewing 17 publications, we found 2 additional studies to be included. </p> <p>In additional searches of CCDANCTR and CENTRAL (December 2011 to April 2013), we found another 288 references. Of these 288 references, we did not find any other publication for inclusion. </p> <p>So, taking together both searches, we found 3947 publications through electronic search strategies, from which we finally included 11 publications with 12 RCTs (see <a href="#CD004044-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD004044-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004044-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In 2004, 13 studies needed a consensus discussion in the fourth step of the search strategy before they were excluded, and in 2013, 5 additional studies needed such a discussion before they were excluded, resulting in a total of 18 excluded studies (see <a href="#CD004044-sec-0054">Excluded studies</a>). </p> <p>In February 2020, from a search of CENTRAL and the CCMD, we identified a total of 2204 publications. After screening for duplicates, we removed 834 articles from the search and we screened a total of 1370 articles for title and abstract. In the second step, we screened 37 full‐text publications. None of these articles met the inclusion criteria of this review (see <a href="#CD004044-fig-0003">Figure 3</a>). Thus, this update in 2021 includes the same studies that were included in the update in 2015 (<a href="./references#CD004044-bbs2-0071" title="WijkstraJ , LijmerJ , BurgerH , CiprianiA , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub4]">Wijkstra 2015</a>). </p> </section> <section id="CD004044-sec-0045"> <h4 class="title">Included studies</h4> <p>See the <a href="./references#CD004044-sec-0161" title="">Characteristics of included studies</a> table for a description of the 12 included RCTs (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). </p> <section id="CD004044-sec-0046"> <h5 class="title">Design</h5> <p>All studies were RCTs comparing the effects of pharmacological interventions for treatment of psychotic depression or for treatment of depression with and without psychotic features, but with data about participants with psychotic features published separately. </p> </section> <section id="CD004044-sec-0047"> <h5 class="title">Sample size</h5> <p>Sample sizes were as follows: <a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; 46; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>: 30; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>: 259; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>: 54; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>: 124; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>: 125; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>: 58; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>: 27; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; 48; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>: 122; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>: 32; and <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>: 22, for a total of 947 participants. </p> </section> <section id="CD004044-sec-0048"> <h5 class="title">Setting</h5> <p>Most studies included inpatients, except <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>, and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>. In <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, 69.1% of participants entered as inpatients. In the studies of Rothschild, participants were treated for at least one week as inpatients. </p> <p>Seven studies were conducted in the United States (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>), 3 in the Netherlands (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), and 2 in Italy (<a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). </p> </section> <section id="CD004044-sec-0049"> <h5 class="title">Participants</h5> <p>All participants fulfilled criteria for major depressive disorder with psychotic features, classified according to a formal classification system (RDC ‐ Research Diagnostic Criteria; <i>DSM‐III; DSM‐IV; DSM‐IV‐TR</i>). Six studies explicitly used a semi‐structured diagnostic interview (<a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>: Schedule for Affective Disorders and Schizophrenia (SADS); <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>: SADS; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>: Brief Psychiatric Rating Scale (BPRS); <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>: SADS; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>: Structured Clinical Interview for DSM‐IV (SCID IV); <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>: SCID IV). These different procedures could have led to differences in participant categories. </p> <p>Seven studies included only participants with unipolar psychotic depression. In <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>, it was possible to exclude bipolar participants from the data. In <a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>, 15.8% (6 out of 38) bipolar participants were included in the data that the study author used in this analysis. However, it is unclear how many of the eight dropouts, who were excluded before analysis, were bipolar participants. The study author was not able to give additional information. Therefore, we decided to assume a random dropout rate. In <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>, 15.5% of participants were bipolar (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>). In <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> and <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>, we were able to exclude bipolar participants with additional information provided by the study authors. <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>, <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, and <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> described types of psychotic symptoms in greater detail. <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a> included only participants with mood congruent delusions. This indicates some heterogeneity in diagnosis with regard to bipolarity. </p> </section> <section id="CD004044-sec-0050"> <h5 class="title">Interventions</h5> <p> <ol id="CD004044-list-0012"> <li> <p>Antidepressant versus placebo was compared in one study (<a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>): amitriptyline (three weeks at least 150 mg) versus placebo; treatment period was four weeks </p> </li> <li> <p>Antipsychotic versus placebo was examined in one arm of the two identical studies of Rothschild (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>): olanzapine (mean 11.9 mg; respectively, 14.0 mg) versus placebo; treatment period was eight weeks </p> </li> <li> <p>Antidepressant versus antidepressant was examined in five studies. In <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>: imipramine (plasma levels imipramine plus its metabolite desmethylimipramine 192 to 521 ng/mL) versus fluvoxamine (plasma level 109 to 325 ng/mL); treatment period was four weeks after predefined blood levels were reached; in <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>: imipramine (plasma levels imipramine plus its metabolite desmethylimipramine 199 to 400 ng/mL) versus mirtazepine (plasma level 49 to 93 ng/mL); treatment period was four weeks after predefined blood levels were reached; in <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>: sertraline (150 mg from day 8) versus paroxetine (50 mg from day 8); treatment period was five weeks; in <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>: venlafaxine (300 mg from day 8) versus fluvoxamine (300 mg from day 8); treatment period was five weeks; and in one arm of <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>: imipramine (plasma levels imipramine plus its metabolite desmethylimipramine 200 to 300 ng/mL) versus venlafaxine (375 mg); treatment period was seven weeks </p> </li> <li> <p>Antipsychotic versus antipsychotic was not compared in any study</p> </li> <li> <p>Antidepressant versus antipsychotic was examined in one arm of <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>: amitriptyline (mean dose 218 mg; 130 to 500 ng/mL) versus perphenazine (mean dose 50 mg; blood level 19 to 113 ng/mL); treatment period was four weeks </p> </li> <li> <p>The combination of antidepressant plus antipsychotic versus placebo was compared in one arm of both identical studies of Rothschild (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>): olanzapine (12.4 mg; respectively, 13.9 mg) plus fluoxetine (23.5 mg; respectively, 22.6 mg) versus placebo; treatment period was eight weeks </p> </li> <li> <p>The combination of antidepressant plus antipsychotic versus placebo plus antidepressant was compared in four studies. In <a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>: amitriptyline (150 to 250 mg) plus perphenazine (24 to 40 mg) versus amoxapine (300 to 500 mg); treatment period was four weeks; in <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>: nortriptyline (mean 63 mg) plus perphenazine (mean 19 mg) versus nortriptyline (mean dose 76 mg); treatment started with nortriptyline, and once nortriptyline blood level was between 50 and 50 ng/mL, random assignment followed; treatment period with nortriptyline plus perphenazine (or placebo) after random assignment was 2 to 16 weeks (total treatment at least four weeks); in one arm of <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>: amitriptyline (mean 170 mg; 18 to 128 ng/mL) plus perphenazine (mean 54 mg; 157 to 690 ng/mL) versus amitriptyline (mean 218 mg; 130 to 500 ng/mL); treatment period was four weeks; and in two arms of <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>: venlafaxine (375 mg) plus quetiapine (600 mg) versus imipramine (plasma levels imipramine plus its metabolite desmethylimipramine 200 to 300 ng/mL) and versus venlafaxine (375 mg); treatment period was 7 weeks </p> </li> <li> <p>The combination of antidepressant plus antipsychotic versus placebo plus antipsychotic was examined in three studies. In one arm of both identical studies of Rothschild (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>): olanzapine (12.4 mg; respectively, 13.9 mg) plus fluoxetine (23.5 mg; respectively, 22.6 mg) versus olanzapine (mean 11.9 mg; respectively, 14.0 mg); treatment period was eight weeks; in one arm of <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>: amitriptyline (mean 170 mg; 18 to 128 ng/mL) plus perphenazine (mean 54 mg; 157 to 690 ng/mL) versus perphenazine (mean dose 50 mg; blood level 19 to 113 ng/mL); treatment period was four weeks; and in <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>: olanzapine (15 to 20 mg) plus sertraline (150 to 200 mg) versus olanzapine (15 to 20 mg); treatment period was 12 weeks </p> </li> </ol> </p> <p>Most of these studies had a washout period before the start of treatment or random assignment, varying from four to seven days. One study had a washout period of two weeks (<a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>). Because of the design of <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a> (all participants used nortriptyline before random assignment to additional perphenazine or placebo), this study was considered a trial without a washout period. The two trials <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a> and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a> had a 'screening period' of three to nine days, leaving unclear whether this was a period in which medication was not allowed. In <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, psychotropics were tapered before random assignment without a washout period. So, heterogeneity is seen in the medication‐free period before treatment. </p> <p>The dosage of psychotropics used in different trials was considered reasonably adequate. However, differences in dosing strategies led to possible bias. In four studies of TCAs, doses were adjusted according to predefined therapeutic plasma levels (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). In <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>, dose adjustment was not based on plasma levels, but afterwards it was found that plasma levels were therapeutic in most participants, although plasma levels of participants receiving TCAs alone were lower compared with those of participants receiving TCA plus antipsychotic. In the two other trials with TCAs, no plasma levels were determined. Dosages in <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a> were at least 150 mg/d, but only during three of the four study weeks. In <a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>, participants received at least 150 mg/d from the third day of the four‐week study period. Amitriptyline 150 mg/d is in the low range of an adequate dosage. In <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a> and <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>, SSRIs (fluvoxamine and mirtazapine) were dosed according to predefined plasma levels. Fixed doses were used in the studies of Zanardi (<a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>): sertraline 150 mg, paroxetine 50 mg, venlafaxine 300 mg, and fluvoxamine 300 mg. In the studies of Rothschild (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>), doses were clinically adjusted: olanzapine 5 to 20 mg and fluoxetine 20 to 80 mg. </p> <p>Differences in additional medication strategies were also noted. In most studies, additional medication was used, such as benzodiazepines (flurazepam up to 30 mg or lorazepam as needed) and anticholinergics. In <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> and <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>, some participants were treated with additional haloperidol, if clinically needed. With information provided by the study authors, we were able to identify these participants in the results and we counted them as dropouts, as in these studies the focus was the comparison of two antidepressants. </p> </section> <section id="CD004044-sec-0051"> <h5 class="title">Outcomes</h5> <p>The primary efficacy outcome was the response rate in each study. It was not possible to transfer study authors' defined response data into rates based on one definition (i.e. at least 50% reduction in HRSD score). Some study authors used response definitions based on what is often considered remission. In addition, some study authors included psychotic symptoms in their response definition. In the absence of a better option, we decided to use the response data as reported by study authors. </p> <p>Differences in outcome measures were noted. In most trials, the HRSD was used as an outcome measure. However, different versions of the HRSD were used, and study authors used different definitions of response. In six trials, the response definition was a reduction of at least 50% in HRSD score compared with baseline (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). In four studies, study authors' definition of response was actually comparable with a frequently used definition of remission (<a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). </p> <p>In five studies, the response definition also included psychotic symptoms (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> and <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> used a response criterion of HRSD‐17 less than 50%; <a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a> 50% or less; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a> and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a> HRSD‐24 less than 50%; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> less than 50% plus less than 15%; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a> HRSD‐17 less than 7 and no delusions; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a> HRSD‐17 less than 7 and not psychotic, or HRSD‐17 6.5 to 9.5 and not psychotic and a third less of score at entry; and <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a> HRSD‐17 less than 11 and BPRS score for items 11, 12, and 15 of 1 or 2 (i.e. not psychotic). In <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, remission was defined as HRSD‐17 score less than 11 and no psychosis; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> HRSD‐21 less than 8 and DDERS (Dimensions of Delusional Experience Rating Scale) of 0; and <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a> HRSD‐21 less than 9 and DDERS of 0. In <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> and <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>, no minimum HRSD score was applied as an inclusion criterion. </p> <p>In addition to response rates based on the above criteria used by study authors, several studies reported remission rates separately (<a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>: HRSD‐17 &lt; 8; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a> and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>: Hamilton Depression Rating Scale (HAMD)‐24 &lt; 9 for two consecutive visits; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>: HRSD‐17 &lt; 8). In two studies, trial authors' definition of response is the same as what is nowadays considered the definition of remission (<a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a> and <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>: HRSD‐17 &lt; 7). </p> </section> <section id="CD004044-sec-0052"> <h5 class="title">Dropout rates</h5> <p>Overall dropout rates for the primary outcome were available for all studies. Dropout rates due to adverse effects were available for six studies (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). Dropout rates due to adverse effects were not based on ITT analysis for three studies (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>); were unavailable for one study (<a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>); and were the same as overall dropout rates for two studies (<a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). Dropouts specifically due to mortality or suicide were not reported, so we decided to extract only overall dropout rates. </p> <p>Overall dropout rates for included studies varied from 9% to 45%. In <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>, the reported dropout rate was 10%. However, when haloperidol‐treated participants were included as dropouts, as was our approach, the dropout rate was 40%. In the two multi‐centre trials with olanzapine/fluoxetine (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>), dropout rates were 41%, and even higher non‐completion rates (56%) were reported. Most often, no statistically significant differences in overall dropout rates were noted between any of the treatments, neither in individual studies nor after pooling of studies. </p> </section> <section id="CD004044-sec-0053"> <h5 class="title">Prior treatment</h5> <p><a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> provided information on prior treatment in the current episode. However, these data were not available for the subgroup with psychotic depression. In <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>, some data about prior treatment are available. The other studies did not provide information on prior treatment of the current episode. Therefore, it was not possible to examine differences in treatment response in relation to non‐response to prior treatment(s). </p> </section> </section> <section id="CD004044-sec-0054"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD004044-sec-0162" title="">Characteristics of excluded studies</a> table. </p> <p>Reasons for exclusion include open study design, problems with diagnosis (exclusion of psychotic features, unclear diagnostic procedure, no adequate data on the MDD subgroup with psychotic features, &gt; 20% bipolar participants included, and no additional data to exclude bipolar participants), too few participants with psychotic depression (N = 3), problems with treatments (continuation of mood stabilisers, additional treatment with other psychotropics), pooled analysis of studies that were included in the previously updated review, and no possibility to extract ITT data. </p> <p>In the most recent search, in 2020, we identified three new articles on the treatment of psychotic depression with mifepristone (<a href="./references#CD004044-bbs2-0016" title="Blasey CM, BlockTS , BelanoffJK , RoeRL . Efficacy and safety of mifepristone for the treatment of psychotic depression. Journal of Clinical Psychopharmacology2011;31(4):436-40. ">Blasey 2011</a>; <a href="./references#CD004044-bbs2-0017" title="BlockT , PetridesG , KushnerH , KalinN , BelanoffJ , SchatzbergA . Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression. Journal of Clinical Psychopharmacology2017;37(5):505-11. ">Block 2017</a>; <a href="./references#CD004044-bbs2-0018" title="BlockTS , KushnerH , KalinN , NelsonC , BelanoffJ , SchatzbergA . Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biological Psychiatry2018;84(1):46-54. ">Block 2018</a>). We excluded all three studies because in addition to mifepristone or placebo, as all patients received an unspecified antidepressant in a non‐standardised way as additional medication.  </p> <p>In <a href="./references#CD004044-bbs2-0016" title="Blasey CM, BlockTS , BelanoffJK , RoeRL . Efficacy and safety of mifepristone for the treatment of psychotic depression. Journal of Clinical Psychopharmacology2011;31(4):436-40. ">Blasey 2011</a>, participants received mifepristone or placebo during the first seven days and "throughout the study [...] one of the following antidepressant medications at standard clinical doses: bupropion, venlafaxine, fluoxetine, citalopram, escitalopram, mirtazepine, paroxetine, or sertraline". In <a href="./references#CD004044-bbs2-0017" title="BlockT , PetridesG , KushnerH , KalinN , BelanoffJ , SchatzbergA . Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression. Journal of Clinical Psychopharmacology2017;37(5):505-11. ">Block 2017</a>, participants also received mifepristone or placebo during the first seven days and from day 8 to day 56, "a single FDA‐approved [<i>but further unspecified</i>] antidepressant". <a href="./references#CD004044-bbs2-0018" title="BlockTS , KushnerH , KalinN , NelsonC , BelanoffJ , SchatzbergA . Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biological Psychiatry2018;84(1):46-54. ">Block 2018</a> pooled data from five previous studies and reported that higher plasma levels of mifepristone were associated with better response for psychotic symptoms. In this study, participants also received mifepristone or placebo during the first seven days and "an FDA approved <i>[but further unspecified</i>] antidepressant for 7 or 8 weeks" during the 8‐week trial. As in none of these three studies treatment with the antidepressant was standardised (i.e. all patients receiving the same regimen with a single but also the same antidepressant for all patients at a fixed dose and during a fixed period, e.g. throughout the whole study), the different antidepressant regimens may have obscured the effect of mifepristone; therefore, these studies were not enrolled in the current review. </p> </section> </section> <section id="CD004044-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD004044-fig-0001">Figure 1</a> and <a href="#CD004044-fig-0002">Figure 2</a> and the <a href="./references#CD004044-sec-0161" title="">Characteristics of included studies</a> table. </p> <section id="CD004044-sec-0056"> <h4 class="title">Allocation</h4> <p>All included studies were RCTs. Randomisation was fully described in two studies (<a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), and it was described in part in three studies (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>). In the other seven studies, randomisation was mentioned as such, but methods of randomisation were not delineated. </p> <p>(Random sequence generation: 7 studies unclear risk and 5 low risk of bias; allocation concealment: 10 unclear risk and two low risk of bias.) </p> </section> <section id="CD004044-sec-0057"> <h4 class="title">Blinding</h4> <p>All studies were double‐blind studies, but blinding itself was not always adequately described in the methods section of the study. Blinding was adequately described in eight studies (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). The method of blinding was not explicitly described in the remaining four studies (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>).However, as study authors explicitly state the double‐blind condition of their studies, we have no reason to doubt that these double‐blind conditions pertained to both investigators/assessors and participants. </p> <p>(Blinding of participants: 2 studies unclear risk and 10 studies low risk of bias; blinding of personnel: 2 studies unclear risk and 10 studies low risk of bias; blinding of outcome assessors: 5 studies unclear risk and 7 studies low risk of bias.) </p> </section> <section id="CD004044-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>The primary efficacy outcome was the response rate (of depression). It was not possible to transfer study authors' defined response data into rates based on a single definition (i.e. 50% reduction in HRSD score). Four studies used response definitions based on what is often considered remission (e.g. HAMD &lt; 8 or 10) (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>); in the absence of a better option (no response data according to our definition), we decided to use the response data as defined by study authors. In addition, six studies included psychotic symptoms in their response definition (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>); in these cases we also followed the study authors, with the preference to use response of depression rather than response of psychosis. </p> <p>In 8 of the 12 studies, we recalculated intention‐to‐treat response rates using all randomly assigned participants as the denominator. Of 46 participants in <a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>, 8 were dropped from the study before receiving two full weeks of active medication. These participants were excluded from analysis by the study author, but we included them in our ITT analysis. In <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> and <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>, we counted participants treated with haloperidol as dropouts because haloperidol treatment for these participants was started after random assignment, in part to keep them in the study. Thus, treatment with haloperidol is considered a potential bias with regard to the effect of study medication as well as dropouts. <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a> excluded six dropouts after random assignment to perphenazine or placebo. We included them in our ITT analysis. In <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a> and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>, 7% and 9%, respectively, of randomly assigned participants were lost before baseline plus one visit. These participants were excluded from the study analysis but were included in our ITT analysis. In both studies of Spiker (<a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>), seven dropouts were excluded from their analyses, but we included them in our ITT analysis. </p> <p>For the secondary outcome of change in symptom severity, we decided to refrain from using continuous data from observer depression severity scales. In two studies (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>), continuous data were available for the total group (psychotic and non‐psychotic) but not for the psychotic subgroup. In four studies, continuous data were not available (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>). In <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>, baseline and final mean HRSD data were given, but it was impossible to exclude bipolar participants from these data and convert the data to ITT data. In the studies of Rothschild (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>), only last observation carried forward (LOCF) continuous data were available, and in this study, dropout was very high. Pooling of data from the three remaining studies are useless because three different comparisons are studied: antidepressant versus antidepressant with no ITT data (<a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>); antidepressant + antipsychotic versus antipsychotic (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>); and antidepressant + antipsychotic versus antidepressant (<a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). </p> <p>(Incomplete data: 1 study high risk, 3 studies unclear risk, and 8 studies low risk of bias.) </p> </section> <section id="CD004044-sec-0059"> <h4 class="title">Selective reporting</h4> <p>All studies used generally accepted outcomes. We judged <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a> and <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> to be at low risk of reporting bias, as the protocols were available and no post‐protocol changes in outcome measures had been made (except in <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>, which used remission as an outcome not stated in the protocol but with reasonable argument that remission has become a generally accepted outcome measure). The remaining ten studies were at unclear risk of reporting bias. </p> </section> <section id="CD004044-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>The subgroup of psychotic depressed participants was not stratified before random assignment in any of these studies (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>). Subgroup analyses are more likely to be carried out if the results for primary outcomes are not significant, or if they are more likely to be reported for groups for whom a significant result was found. However, in this review, we ourselves analysed subgroup data in studies that primarily reported on participants with depression with and without psychotic features. </p> <p>As described under <a href="#CD004044-sec-0043">Description of studies</a>, clinical heterogeneity is seen within the results. </p> <p>In six studies, response definition included response with regard to psychotic symptoms (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>), and in the other studies (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), response rates concerned only change in severity of depression. In our analysis, we looked only for response of depression leading to a possible bias favouring antidepressants over antipsychotics. </p> <p>(Other biases together: 6 studies high risk and 6 studies unclear risk of bias.)</p> </section> </section> <section id="CD004044-sec-0061"> <h3 class="title" id="CD004044-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD004044-tbl-0001"><b>Summary of findings 1</b> Antidepressant compared to placebo for psychotic depression</a>; <a href="./full#CD004044-tbl-0002"><b>Summary of findings 2</b> Antipsychotic compared to placebo for psychotic depression</a>; <a href="./full#CD004044-tbl-0003"><b>Summary of findings 3</b> Antidepressant compared to antidepressant for psychotic depression</a>; <a href="./full#CD004044-tbl-0004"><b>Summary of findings 4</b> Antidepressant compared to antipsychotic for psychotic depression</a>; <a href="./full#CD004044-tbl-0005"><b>Summary of findings 5</b> Antidepressant plus antipsychotic compared to placebo for psychotic depression</a>; <a href="./full#CD004044-tbl-0006"><b>Summary of findings 6</b> Antidepressant plus antipsychotic compared to placebo plus antipsychotic for psychotic depression</a>; <a href="./full#CD004044-tbl-0007"><b>Summary of findings 7</b> Antidepressant plus antipsychotic compared to placebo plus antidepressant for psychotic depression</a>; <a href="./full#CD004044-tbl-0008"><b>Summary of findings 8</b> Antidepressant plus antipsychotic compared to placebo plus the same antidepressant for psychotic depression</a> </p> <p>All included studies reported effects on depressive symptoms as their primary outcome. The way these were characterised for each study is listed in the <a href="#CD004044-sec-0045">Included studies</a> section above and in the 'Summary of findings' tables. Further details on the scales are given under <a href="./references#CD004044-sec-0161" title="">Characteristics of included studies</a>. </p> <p>For the secondary outcome of change in symptom severity, extracting continuous data from observer depression severity scales was not possible because in seven studies, we were not able to convert these data according to intention‐to‐treat analysis (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>), and in two other studies, no continuous data were reported (<a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). </p> <section id="CD004044-sec-0062"> <h4 class="title">Comparison 1. Antidepressant versus placebo</h4> <section id="CD004044-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0064"> <h6 class="title">1.1 Efficacy response rates</h6> <p><a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a> compared amitriptyline with placebo. The sample size (N = 27) was very small. There is insufficient data to conclude whether there is a difference between amitryptiline and placebo (risk ratio (RR) 8.40, 95% confidence interval (CI) 0.50 to 142.27; participants = 27, studies = 1; <a href="./references#CD004044-fig-0004" title="">Analysis 1.1</a>) Certainty of the evidence is rated very low. </p> </section> <section id="CD004044-sec-0065"> <h6 class="title">1.2 Harm: overall dropout rate during acute treatment</h6> <p><a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a> There is insufficient date to conclude that there is no difference in dropout rates between amitriptyline and placebo (RR 1.24, 95% CI 0.34 to 4.51; participants = 27, studies = 1; <a href="./references#CD004044-fig-0005" title="">Analysis 1.2</a>) Certainty of the evidence is rated very low. </p> </section> </section> <section id="CD004044-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0067"> <h6 class="title">1.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0068"> <h6 class="title">1.4 Change from baseline</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0069"> <h6 class="title">1.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0070"> <h6 class="title">1.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0071"> <h4 class="title">Comparison 2. Antipsychotic versus placebo</h4> <section id="CD004044-sec-0072"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0073"> <h6 class="title">2.1 Efficacy response rates</h6> <p>Two identical studies compared an antipsychotic with placebo (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). Pooling these studies shows it is very uncertain to conclude that olanzapine is not more effective than placebo (RR 1.13, 95% CI 0.74 to 1.73; P = 0.57; <a href="./references#CD004044-fig-0006" title="">Analysis 2.1</a>). Certainty of the evidence is rated very low. </p> </section> <section id="CD004044-sec-0074"> <h6 class="title">2.2 Harm: overall dropout rate during acute treatment</h6> <p>Meta‐analysis of two studies (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>) show it is very uncertain whether there is no difference in dropout rates between olanzapine and placebo groups (RR 0.79, 95% CI 0.57 to 1.08; P = 0.14; <a href="./references#CD004044-fig-0007" title="">Analysis 2.2</a>). Certainty of the evidence is rated very low. </p> </section> </section> <section id="CD004044-sec-0075"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0076"> <h6 class="title">2.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0077"> <h6 class="title">2.4 Change from baseline</h6> <p>For the secondary outcome, change in symptom severity, it was not possible to extract continuous data from observer depression severity scales; we were not able to convert these data according to ITT analysis (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). </p> </section> <section id="CD004044-sec-0078"> <h6 class="title">2.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0079"> <h6 class="title">2.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0080"> <h4 class="title">Comparison 3. Antidepressant versus antidepressant</h4> <section id="CD004044-sec-0081"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0082"> <h6 class="title">3.1 Efficacy response rates</h6> <p>Five studies compared two different antidepressants directly (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). Due to heterogeneity in the types of antidepressants, it was not feasible to perform a meta‐analysis. The evidence as a whole was rated of very low certainty. Therefore, it is uncertain whether there are any differences in effectiveness between antidepressants. </p> <p><a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> found that imipramine may be more effective than fluvoxamine (RR 2.10, 95% CI 1.06 to 4.17; <a href="./references#CD004044-fig-0008" title="">Analysis 3.1</a>), <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> found  that imipramine may be more effective than mirtazapine (RR 3.00, 95% CI 1.01 to 8.95; <a href="./references#CD004044-fig-0008" title="">Analysis 3.1</a>), and <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> found that sertraline may be more effective than paroxetine (RR 3.37, 95% CI 1.19 to 9.57; <a href="./references#CD004044-fig-0008" title="">Analysis 3.1</a>). The other two studies found no difference between the two study arms (<a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a> found no difference between fluvoxamine and venlafaxine (RR 1.50, 95% CI 0.82 to 2.75; <a href="./references#CD004044-fig-0008" title="">Analysis 3.1</a>). In the largest study (N = 81), <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> found no difference between imipramine and venlafaxine (RR 1.57, 95% CI 0.93 to 2.67; <a href="./references#CD004044-fig-0008" title="">Analysis 3.1</a>). </p> </section> <section id="CD004044-sec-0083"> <h6 class="title">3.2 Harm: overall dropout rate during acute treatment</h6> <p>Two different antidepressants were compared directly with each other in five studies (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>). Due to heterogeneity between studies (i.e. in all five studies, different antidepressants were used), it was not feasible to perform a meta‐analysis. </p> <p>None of the five studies found evidence of a difference between antidepressants.The evidence as a whole was rated of very low certainty. Therefore, it is uncertain whether there are any differences in drop out rate between antidepressants. In the largest study (N = 81), <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> found no difference between imipramine and venlafaxine (RR 0.81, 95% CI 0.33 to 2.03; <a href="./references#CD004044-fig-0009" title="">Analysis 3.2</a>). <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> noted no difference between imipramine and mirtazapine (RR 0.50, 95% CI 0.19 to 1.31; <a href="./references#CD004044-fig-0009" title="">Analysis 3.2</a>). <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> reported no difference between imipramine and fluvoxamine (RR 2.00, 95% CI 0.40 to 9.95; <a href="./references#CD004044-fig-0009" title="">Analysis 3.2</a>), and <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> noted no difference between sertraline and paroxetine (RR 0.20, 95% CI 0.01 to 3.74; <a href="./references#CD004044-fig-0009" title="">Analysis 3.2</a>). In the final study (<a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>), investigators reported no difference between fluvoxamine and venlafaxine (RR 0.07, 95% CI 0.00 to 1.20; <a href="./references#CD004044-fig-0009" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD004044-sec-0084"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0085"> <h6 class="title">3.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0086"> <h6 class="title">3.4 Change from baseline</h6> <p>Pooling was not possible because different antidepressants were used.</p> </section> <section id="CD004044-sec-0087"> <h6 class="title">3.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0088"> <h6 class="title">3.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0089"> <h4 class="title">Comparison 4. Antipsychotic versus antipsychotic</h4> <p>No study compared an antipsychotic with another antipsychotic.</p> </section> <section id="CD004044-sec-0090"> <h4 class="title">Comparison 5. Antidepressant versus antipsychotic</h4> <section id="CD004044-sec-0091"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0092"> <h6 class="title">5.1 Efficacy response rates</h6> <p><a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a> compared an antidepressant with an antipsychotic  and found no evidence of a difference between perphenazine and amitriptyline. However, the sample size (N = 36) was very small (RR 2.09, 95% CI 0.64 to 6.82; <a href="./references#CD004044-fig-0010" title="">Analysis 4.1</a>; Certainty of the evidence is rated very low. </p> </section> <section id="CD004044-sec-0093"> <h6 class="title">5.2 Harm: overall dropout rate during acute treatment</h6> <p><a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a> also found no evidence of difference in dropout rates between perphenazine and amitriptyline groups but again the evidence is limited by a very small sample size(RR 1.79, 95% CI 0.18 to 18.02; ) Certainty of the evidence is rated very low. </p> </section> </section> <section id="CD004044-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0095"> <h6 class="title">5.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0096"> <h6 class="title">5.4 Change from baseline</h6> <p>For the secondary outcome, change in symptom severity, it was not possible to extract continuous data from observer depression severity scales because in the only study that performed this comparison (<a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>), we were not able to convert these data according to intention‐to ‐treat analysis. </p> </section> <section id="CD004044-sec-0097"> <h6 class="title">5.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0098"> <h6 class="title">5.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0099"> <h4 class="title">Comparison 6. Antidepressant plus antipsychotic versus placebo</h4> <section id="CD004044-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0101"> <h6 class="title">6.1 Efficacy response rates</h6> <p>Two identical studies compared the combination of fluoxetine and olanzapine versus placebo (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). Pooling these studies suggests it is very uncertain to conclude whether or not the combination of an antidepressant with an antipsychotic is more efficacious than placebo alone  (RR 1.86, 95% CI 1.23 to 2.82; P = 0.003; <a href="./references#CD004044-fig-0012" title="">Analysis 5.1</a>). Certainty of the evidence is rated very low. </p> </section> <section id="CD004044-sec-0102"> <h6 class="title">6.2 Harm: overall dropout rate during acute treatment</h6> <p>Meta‐analysis of two studies ‐ <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a> ‐ found no evidence of difference in dropout rates (RR 0.75, 95% CI 0.48 to 1.18; P = 0.21; <a href="./references#CD004044-fig-0013" title="">Analysis 5.2</a>). However, substantial heterogeneity was present (I² = 76%): in <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>, the dropout rate was higher for placebo, and in <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>, it was higher for olanzapine. Certainty of the evidence is rated very low. </p> </section> </section> <section id="CD004044-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0104"> <h6 class="title">6.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0105"> <h6 class="title">6.4 Change from baseline</h6> <p>For the secondary outcome, change in symptom severity, it was not possible to extract continuous data from observer depression severity scales because for these two studies (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>), we were not able to convert these data according to intention‐to ‐treat analysis. </p> </section> <section id="CD004044-sec-0106"> <h6 class="title">6.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0107"> <h6 class="title">6.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0108"> <h4 class="title">Comparison 7. Antidepressant plus antipsychotic versus placebo plus antipsychotic</h4> <section id="CD004044-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0110"> <h6 class="title">7.1 Efficacy response rates</h6> <p>Four studies compared the combination of an antidepressant plus an antipsychotic with antipsychotic monotherapy (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). Pooling of data from all four studies suggests that the combination of an antidepressant with an antipsychotic may be more efficacious than an antipsychotic alone (RR 1.83, 95% CI 1.40 to 2.38; P = 0.00001; <a href="./references#CD004044-fig-0014" title="">Analysis 6.1</a>). Certainty of the evidence is rated low. </p> </section> <section id="CD004044-sec-0111"> <h6 class="title">7.2 Harm: overall dropout rate during acute treatment</h6> <p>Pooling of all four studies ‐ <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a> ‐ did not reveal a difference in dropout rates between the combination of an antidepressant and an antipsychotic and an antipsychotic alone (RR 0.79, 95% CI 0.63 to 1.01; P = 0.06; <a href="./references#CD004044-fig-0015" title="">Analysis 6.2</a>). However, there was considerable heterogeneity (I² = 63%), likely caused by the identical <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a> and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a> studies, in which dropout rates were very high but also different between the two studies. Certainty of the evidence is rated very low. </p> </section> </section> <section id="CD004044-sec-0112"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0113"> <h6 class="title">7.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0114"> <h6 class="title">7.4 Change from baseline</h6> <p>For the secondary outcome, change in symptom severity, it was not possible to extract continuous data from observer depression severity scales because in three studies (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>), we were not able to convert these data according to ITT analysis. </p> </section> <section id="CD004044-sec-0115"> <h6 class="title">7.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0116"> <h6 class="title">7.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0117"> <h4 class="title">Comparison 8. Antidepressant plus antipsychotic versus placebo plus antidepressant</h4> <section id="CD004044-sec-0118"> <h5 class="title">Primary outcomes</h5> <section id="CD004044-sec-0119"> <h6 class="title">8.1 Efficacy response rates</h6> <p>Four studies (five comparisons) compared the combination of an antidepressant plus an antipsychotic with antidepressant monotherapy (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). Pooling of these four studies with five analyses suggests that the combination of an antidepressant plus an antipsychotic may be more effective than an antidepressant alone (RR 1.42, 95% CI 1.11 to 1.80; P = 0.002; <a href="./references#CD004044-fig-0016" title="">Analysis 7.1</a>). Certainty of the evidence is rated low. </p> <p>The unplanned subgroup analysis of the three studies that compared the same antidepressant in both arms (<a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>) also suggests that the combination of an antidepressant with an antipsychotic is more effective than the antidepressant alone (RR 1.70, 95% CI 1.19 to 2.43; P = 0.003; <a href="./references#CD004044-fig-0018" title="">Analysis 8.1</a>). Certainty of the evidence is rated low. </p> </section> <section id="CD004044-sec-0120"> <h6 class="title">8.2 Harm: overall dropout rate during acute treatment</h6> <p>It is very uncertain whether there were any differences between an antidepressant plus an antipsychotic versus an antidepressant alone after pooling of all four studies (RR 0.91, 95% CI 0.55 to 1.50; P = 0.69; <a href="./references#CD004044-fig-0017" title="">Analysis 7.2</a>). Certainty of the evidence is rated very low. </p> <p>In the unplanned subgroup analysis of the three studies that compared the same antidepressant in both arms (<a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), it was also every uncertain whether there were any  differences between interventions (RR 1.04, 95% CI 0.52 to 0.91; P = 0.91; <a href="./references#CD004044-fig-0019" title="">Analysis 8.2</a>). Certainty of the evidence is rated very low. </p> </section> </section> <section id="CD004044-sec-0121"> <h5 class="title">Secondary outcomes</h5> <section id="CD004044-sec-0122"> <h6 class="title">8.3 Remission</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0123"> <h6 class="title">8.4 Change from baseline</h6> <p>For the secondary outcome, change in symptom severity, it was not possible to extract continuous data from observer depression severity scales because we were not able to convert these data according to intention‐to‐treat analysis. </p> </section> <section id="CD004044-sec-0124"> <h6 class="title">8.5 Quality of life</h6> <p>No study measured this outcome.</p> </section> <section id="CD004044-sec-0125"> <h6 class="title">8.6 Dropout rate due to adverse effects</h6> <p>No study measured this outcome.</p> </section> </section> </section> <section id="CD004044-sec-0126"> <h4 class="title">Comparison 9. Mifepristone versus placebo</h4> <p>No study compared mifepristone with a placebo</p> </section> <section id="CD004044-sec-0127"> <h4 class="title">Comparison 10. Mifepristone plus antidepressant versus placebo plus antidepressant</h4> <p>No study compared mifepristone plus an antidepressant with a placebo plus an antidepressant.</p> </section> <section id="CD004044-sec-0128"> <h4 class="title">Comparison 11. Other psychopharmacological agents versus placebo</h4> <p>No study compared other psychopharmacological agents with a placebo.</p> </section> <section id="CD004044-sec-0129"> <h4 class="title">Comparison 12. Other psychopharmacological agents plus antidepressant versus placebo plus antidepressant </h4> <p>No study compared this.</p> </section> <section id="CD004044-sec-0130"> <h4 class="title">Subgroup and sensitivity analyses</h4> <p><a href="./references#CD004044-fig-0018" title="">Analysis 8.1</a> and <a href="./references#CD004044-fig-0019" title="">Analysis 8.2</a> (in which an antidepressant plus an antipsychotic is compared with the same antidepressant plus placebo) were unplanned sensitivity analyses. </p> <p>Because of lack of data, other subgroup analyses were not possible.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004044-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004044-sec-0131"></div> <p>Despite our new search of the literature (screening more than 1370 abstracts and reading 37 full articles), we identified no additional randomised controlled trials (RCTs) from April 2013 up to February 2020 on pharmacological treatment with an antidepressant, an antipsychotic, or another psychopharmacological agent such as mifepristone, or the combination of any of these drugs for participants with a major depressive disorder with a current episode with psychotic features (unipolar psychotic depression). </p> <p>In addition to nine studies whose main focus was treatment of participants with psychotic depression, we were able to find three studies that reported separately on effects on subgroups of participants with psychotic depression. The authors of two further studies provided us with additional information on results for the subgroup of psychotically depressed participants in their studies of both psychotic and non‐psychotic depressed patients. In our previous review, we invited authors of several studies to provide us with subgroup data if available, so we could use these data in our review, but we did not receive any data. </p> <p>We also identified several studies on the efficacy of mifepristone. However, we could not include any of these studies because all study participants also received unspecified antidepressants in a non‐standardised way as additional medication.  </p> <p>Thus, for this update, we found no new studies fulfilling the methodological inclusion criteria of this review, which (again) illustrates that this most severe form of depression is highly under‐investigated. One probable reason for this is that it is very difficult to conduct RCTs in patients with psychotic depression. These patients often are not only psychotic but are very anxious or physically ill. Moreover, they are often offered electroconvulsive therapy (ECT) directly without a trial of pharmacological treatment. Finally, many patients with psychotic depression are not able or are reluctant to give informed consent, or they tend to withdraw their consent (<a href="./references#CD004044-bbs2-0071" title="WijkstraJ , LijmerJ , BurgerH , CiprianiA , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub4]">Wijkstra 2015</a>). </p> <section id="CD004044-sec-0132"> <h3 class="title" id="CD004044-sec-0132">Summary of main results</h3> <p> <ol id="CD004044-list-0013"> <li> <p>Because of lack of included studies from April 2013 to February 2020, results of the previous update from 2015 are still valid (<a href="./references#CD004044-bbs2-0071" title="WijkstraJ , LijmerJ , BurgerH , CiprianiA , GeddesJ , NolenWA . Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD004044. [DOI: 10.1002/14651858.CD004044.pub4]">Wijkstra 2015</a>) </p> </li> <li> <p>Suggestions for the efficacy of the combination of an antidepressant plus an antipsychotic (i.e. fluoxetine plus olanzapine) was derived from two identical placebo‐controlled RCTs (RR 1.86, 95% CI 1.23 to 2.82; P = 0.003; <a href="./references#CD004044-fig-0012" title="">Analysis 5.1</a>) (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>) </p> </li> <li> <p>We also found suggestions for efficacy of the combination of an antidepressant plus an antipsychotic compared to antidepressant monotherapy. Pooling of four studies (with five comparisons) that compared the combination of an antidepressant plus an antipsychotic with antidepressant monotherapy showed a significant difference favouring the combination (RR 1.42, 95% CI 1.11 to 1.80; P = 0.002; <a href="./references#CD004044-fig-0016" title="">Analysis 7.1</a>) (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). When the two comparisons with a different antidepressant are left out (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; and one comparison in <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), this difference remains (RR 1.70, 95% CI 1.19 to 2.43; P = 0.003; <a href="./references#CD004044-fig-0018" title="">Analysis 8.1</a>). Thus, it can be concluded that the combination should be preferred over an antidepressant alone </p> </li> <li> <p>There are also suggestions that the  combination of an antidepressant plus an antipsychotic is more effective than antipsychotic monotherapy. Pooling of four studies that compared the combination of an antidepressant plus an antipsychotic with antipsychotic monotherapy shows a difference favouring the combination (RR 1.83, 95% CI 1.40 to 2.38; P = 0.00001; <a href="./references#CD004044-fig-0014" title="">Analysis 6.1</a>) (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>) </p> </li> <li> <p>No randomised controlled data are available to lead to the conclusion that monotherapy with an antidepressant is efficacious for the treatment of psychotic depression. Only one small study compared monotherapy with an antidepressant (amitriptyline) with placebo and reported no difference (RR 8.40, 95% CI 0.50 to 142.27; <a href="./references#CD004044-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>) </p> </li> <li> <p>Also no randomised controlled data are available to lead to the conclusion that monotherapy with an antipsychotic alone is efficacious. Two identical studies compared monotherapy with an antipsychotic (olanzapine) with placebo (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). Pooling of these two studies does not reveal a difference (RR 1.13, 95% CI 0.74 to 1.73; <a href="./references#CD004044-fig-0008" title="">Analysis 3.1</a>) </p> </li> <li> <p>We were not able to collect data on prior treatments. So we could not address the second objective of our review: to assess whether differences in response to treatment in the current episode would be related to non‐response to prior treatment(s) </p> </li> <li> <p>Regarding acceptability of treatment (dropout, adverse effects) and quality of life, we were only able to collect data only on overall dropout. In all studies except <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, no differences in overall dropout rates were reported between any of the treatment groups including placebo, neither in individual studies nor after pooling of studies. With this rather rough measure, we did not find overall differences in overall acceptability of treatments. In <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>, fewer dropouts were reported in the group treated with the combination of olanzapine plus sertraline than in the group treated with olanzapine alone (RR 1.43, 95% CI 1.08 to 1.88). Study authors suggest that higher attrition rates among participants treated with olanzapine plus sertraline may be attributable to insufficient response in the olanzapine‐treated group </p> </li> <li> <p>We found indication of heterogeneity dropout data only in instances where the two identical studies of Rothschild were included (<a href="./references#CD004044-fig-0009" title="">Analysis 3.2</a>; <a href="./references#CD004044-fig-0013" title="">Analysis 5.2</a>; <a href="./references#CD004044-fig-0015" title="">Analysis 6.2</a>) (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>). This heterogeneity is probably due to high dropout rates, together with differences in dropout rates between the two studies (in one study (<a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>), the dropout rate was higher for placebo, and in the other study (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>), it was higher for olanzapine) </p> </li> </ol> </p> </section> <section id="CD004044-sec-0133"> <h3 class="title" id="CD004044-sec-0133">Overall completeness and applicability of evidence</h3> <p>Our conclusions are based on only 12 studies that fulfilled our inclusion criteria. Moreover, in the included studies, only a few different antidepressants and antipsychotics were used. Therefore, it remains unclear whether the above conclusions can be extrapolated to other antidepressants and other antipsychotics.  </p> <p>Strictly spoken, evidence that the combination of an antidepressant plus an antipsychotic is more effective than an antidepressant alone has been obtained in only one RCT (<a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), which compared the combination of venlafaxine and quetiapine with venlafaxine alone.  </p> <p>Evidence that the combination of an antidepressant plus an antipsychotic is more effective than an antipsychotic alone has been obtained in four RCTs for only two antipsychotics. More specifically, the combination of amitriptyline and perphenazine was reported more effective than perphenazine alone in one small study (<a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>), and the three other studies involved combinations with olanzapine: in two studies with fluoxetine (<a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>), and in one study with sertraline (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>). </p> <p>Nearly all participants in these studies were inpatients. This of course is a consequence of the severity of the illness and the fact that in clinical practice, most patients with psychotic depression are treated as inpatients. There is also the problem of patients who were not included in the studies: the most severely ill patients who were not able to give informed consent or who were immediately given ECT. All these points limit the generalisability of study results to all patients with psychotic depression. </p> <p>These problems ans also  the quality of diagnostic assessment can restrict generalisation of findings to all patients with psychotic depression, leaving aside the problem of establishing the diagnosis of psychotic depression in clinical reality. </p> </section> <section id="CD004044-sec-0134"> <h3 class="title" id="CD004044-sec-0134">Quality of the evidence</h3> <p>The strength of this review and its conclusion is that only randomised controlled studies were included, and only intention‐to‐treat (ITT) data were used in the analyses. </p> <p>Several factors limit our confidence in the findings of this review. There are a number of limitations of the included studies that impact the quality of the evidence they provide. We rated the overall certainty of evidence in the meta‐analyses to be low to very low (using the GRADE criteria). </p> <p>Most studies were relatively small. Only four RCTs had a more or less adequate sample size: <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a> and <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>: with olanzapine 48 and 53 participants, with placebo 51 and 49 participants, but only 25 and 23 olanzapine plus fluoxetine, respectively; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>: with olanzapine + sertraline 129 and sertraline 130 participants; and <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>: imipramine 42, venlafaxine 39, and venlafaxine + quetiapine 41 participants.  </p> <p>As with all systematic reviews, publication bias is a potentially serious source of bias. Too few studies were identified to allow further investigation into the possibility of publication bias (e.g. by making funnel plots). However, the fact that in these mostly small trials, five (50%) found a significant difference between two active treatments is suggestive of publication bias. </p> <p>Allocation concealment, especially in older studies, was not explicitly described. Although we do not assume allocation concealment to be a real bias, this is of course unsure. </p> <p>Dosages of antidepressants and antipsychotics used in the different trials were considered reasonably adequate. However, differences in dosing strategies were noted, leading to possible bias. Differences in additional medication strategies and differences in treatment periods were also reported (see paragraph about Other potential sources of bias for the different diagnotic procedures and different outcome measures used in the different studies). </p> <p>We cannot rule out the possibility of differences in the diagnostic assessment of participants and thus in the quality of the diagnosis across studies. Although it was reported in all publications that participants included in the trials fulfilled criteria for a major depressive episode with psychotic features, according to a specified diagnostic classification system (Research Diagnostic Criteria (RDC), <i>Diagnostic and Statistical Manual of Mental Disorders (DSM)‐III</i> or <i>DSM‐IV</i>), one could doubt the reliability of the diagnoses made in some trials. Six studies used a semi‐structured diagnostic interview (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), and only three studies reported types of psychotic features (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). This leaves open the possibility that for instance the judgement that a feeling or idea of guilt was a guilt delusion was drawn differently across the studies in this review. A comparable diagnostic problem may have played a role in the judgement of whether a participant had a psychotic depression in the course of unipolar disorder or bipolar disorder. Finally, <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a> included a geriatric sample with a mean age of 72 years, leading to the possibility that dementia or another neurological disorder was part of the diagnosis in some participants. </p> <p>We could use only one outcome measure regarding efficacy: response rates as defined by study authors. It was impossible to recalculate these response rates into a standard response rate based on a single definition (e.g. reduction on the Hamilton Rating Scale for Depression (HRSD)‐17 of at least 50% compared with baseline), as many studies used other versions of the HRSD. Moreover, several studies used response definitions that are commonly used for the definition of remission. </p> <p>In addition, the different studies did not use other outcome measures to assess remission rates or quality of life. </p> <p> </p> </section> <section id="CD004044-sec-0135"> <h3 class="title" id="CD004044-sec-0135">Potential biases in the review process</h3> <p>One problem is that there does not exist a key word (Mesh Term) for psychotic depression. Therefore, we had to search all RCTs involving depression whether included participants had depression with psychotic features, or whether such participants had been part of the group of included participants and were reported as a separate subgroup. We anticipated in the first version of this review that we might have missed one or more studies. However, we did not receive any information that we had missed any study. Therefore, in this update, we are now rather sure that we indeed have included all published studies. </p> <p>In three studies (<a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a>), the subgroup of psychotic depressed participants was part of a greater group of participants with psychotic and non‐psychotic depression, although the subgroups were not stratified before random assignment. </p> <p>Another potential problem, which was not taken into account in our a priori protocol before this systematic review was performed, is that in five studies, the response definition included response with regard to psychotic symptoms (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0008" title="SpikerDG , KupferDJ . Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders1988;14(1):21-3. ">Spiker 1988</a>; <a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a>), while in the other studies (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0009" title="vanden BroekWW , BirkenhägerTK , MulderPG , BruijnJ , MolemanP . A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology2004;175(4):481-6. ">van den Broek 2004</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>; <a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a>), the response definition concerned only change in severity of depression. As in our analysis, we only looked for the response of depression, and this may have lead to possible bias favouring antidepressants over antipsychotics. </p> </section> <section id="CD004044-sec-0136"> <h3 class="title" id="CD004044-sec-0136">Agreements and disagreements with other studies or reviews</h3> <p>In a review of practice guidelines regarding treatment for psychotic depression (<a href="./references#CD004044-bbs2-0067" title="WijkstraJ , SchubartCD , NolenWA . Treatment of unipolar psychotic depression: the use of evidence in practice guideline. World Journal of Biological Psychiatry2007;24:1-7.">Wijkstra 2007</a>), we found different recommendations based on slightly different studies; most were not re‐analysed. Two guidelines were cautious in their recommendations (<a href="./references#CD004044-bbs2-0054" title="SpijkerJ , BocktingCLH , MeeuwissenJAC , Vliet IM van, EmmelkampPMG , HermensMLM , et al (van namens de Werkgroep Multidisciplinaire richtlijnontwikkeling Angststoornissen/Depressie). Multidisciplinaire richtlijn Depressie (Derde revisie). Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis; 2013. Utrecht: Trimbos Institute. Available at www.nvvp.net/stream/richtlijn-depressie-2013.pdf.">Multidisciplinaire Richtlijn Depressie 2013</a>; <a href="./references#CD004044-bbs2-0056" title="National Institute for Health and Clinical Excellence. The treatment and management of depression in adults (updated version). National Clinical Practice Guideline 90. London: HMSO, 2009.">NICE 2009</a>). <a href="./references#CD004044-bbs2-0056" title="National Institute for Health and Clinical Excellence. The treatment and management of depression in adults (updated version). National Clinical Practice Guideline 90. London: HMSO, 2009.">NICE 2009</a> recommended that "augmenting an [antidepressant] AD with an [antipsychotic] AP should be considered"; and <a href="./references#CD004044-bbs2-0054" title="SpijkerJ , BocktingCLH , MeeuwissenJAC , Vliet IM van, EmmelkampPMG , HermensMLM , et al (van namens de Werkgroep Multidisciplinaire richtlijnontwikkeling Angststoornissen/Depressie). Multidisciplinaire richtlijn Depressie (Derde revisie). Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis; 2013. Utrecht: Trimbos Institute. Available at www.nvvp.net/stream/richtlijn-depressie-2013.pdf.">Multidisciplinaire Richtlijn Depressie 2013</a> recommended "starting treatment with a [tricyclic antidepressant] TCA and if after 4 weeks there is still no response, adding an AP or starting with the combination of a TCA and an AP are reasonable options". The other reviewed guidelines, including the <a href="./references#CD004044-bbs2-0038" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Washington, DC: American Psychiatric Association, 2010.">APA 2010</a> (now updated with no differences regarding treatment for psychotic depression), recommend using the combination of an AD and an AP. None of these guidelines recommended monotherapy with an antipsychotic. These recommendations were not based on a systematic review of data from all available RCTs; they were based on a few studies ‐ some randomised and some open non‐randomised.  </p> <p>Another review and meta‐analysis on the treatment of psychotic depression has been published (<a href="./references#CD004044-bbs2-0043" title="FarahaniA , CorellCU . Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. Journal of Clinical Psychiatry2012;73:486-96.">Farahani 2012</a>), focusing on the comparison of antidepressant or antipsychotic monotherapy with combination treatment. Five studies were included (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0025" title="KünzelHE , AcklN , HatzingerM , HeldK , Holsboer-TrachslerE , IsingM , et al. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - a double-blind multicenter trial. Journal of Psychiatric Research2009;43(7):702-10. ">Künzel 2008</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>). In our review, for this particular comparison, we excluded <a href="./references#CD004044-bbs2-0025" title="KünzelHE , AcklN , HatzingerM , HeldK , Holsboer-TrachslerE , IsingM , et al. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - a double-blind multicenter trial. Journal of Psychiatric Research2009;43(7):702-10. ">Künzel 2008</a> because it is unclear whether less or more than 20% of included participants in the ITT group had a bipolar disorder (see table <a href="#CD004044-sec-0054">Excluded studies</a>). We included in our review the same four other studies (<a href="./references#CD004044-bbs2-0001" title="Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. American Journal of Psychiatry1990;147(9):1203-8. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. Journal of Affective Disorders1993;28(2):125-31. ">Anton 1990</a>; <a href="./references#CD004044-bbs2-0004" title="MulsantBH , SweetRA , RosenJ , PollockBG , ZubenkoGS , FlynnT , et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry2001;62(8):597-604. ">Mulsant 2001</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>; <a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a>), using exactly the same extracted ITT data. The conclusion of this review is consistent with ours: "Combination treatment is more effective than antidepressant monotherapy". For the comparison of an antipsychotic plus an antidepressant versus an antipsychotic, the same four studies with again exactly the same extracted ITT data were included (<a href="./references#CD004044-bbs2-0003" title="AndreescuC , MulsantBH , Peasley-MiklusC , RothschildAJ , FlintAJ , HeoM , et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. Journal of Clinical Psychiatry2007;68(2):194-200. BlumbergerDM , MulsantBH , EmeremniC , HouckP , AndreescuC , MazumdarS , et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research2011;45(7):896-901. FlintAJ . Challenges in conducting a pharmacotherapy study in psychotic depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. No. 63D. MeyersB , RothschildA , GabrieleM , EnglishJ , McSheaM , KamaraT , et al. Effectiveness of selective serotonin reuptake inhibitors combined with antipsychotic medication for the treatment of psychotic depression [STOP-PD; NCT00056472]. ClinicalTrials.gov [http://www.clinicaltrials.gov]2004. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2009;66(8):838-47. MeyersBS , FlintAJ , RothschildAJ , MulsantBH , WhyteEM , Peasley-MiklusC , et al. Errors in table in: a double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry2011;68(6):625-6. MeyersBS . Diagnosis and treatment of psychosis in geriatric major depression. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton, FL. p 83. SchafferA , FlintAJ , SmithE , RothschildAJ , MulsantBH , SzantoK , et al. Correlates of suicidality among patients with psychotic depression. Suicide and Life-Threatening Behavior2008;38(4):403-14. WeissmanJ , FlintA , MeyersB , GhoshS , MulsantB , RothschildA , et al. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research2012;197(3):221-6. ">Meyers 2009</a>; <a href="./references#CD004044-bbs2-0005" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , CoryaSA , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004a</a>; <a href="./references#CD004044-bbs2-0006" title="RothschildAJ , WilliamsonDJ , TohenMF , SchatzbergA , AndersenSW , Van CampenLE , et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. Journal of Clinical Psychopharmacology2004;24(4):365-73. WilliamsonDJ , AndersenSW , CampenLE , SangerTM , PaulS , et al. Olanzapine-fluoxetine combination for difficult-to-treat depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans; LA:NR549. ">Rothschild 2004b</a>; <a href="./references#CD004044-bbs2-0007" title="SpikerD , PerelJM , HaninI , DealyRS , GriffinSJ , SoloffPH , et al. The pharmacological treatment of delusional depression: part II. Journal of Clinical Psychopharmacology1986;6(6):339-42. SpikerDG , HaninI , PerelJM , CofskyJE , RossiAJ , SorisioD . Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin1982;18(4):184-6. SpikerDG , WeissJC , DealyRS , GriffinSJ , HaninI , NeilJF , et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry1985;142(4):430-6. ">Spiker 1985</a>), leading in both reviews to the same conclusion: "Combination treatment is more effective than antipsychotic monotherapy". As in our review, no differences were reported in overall dropout rates across all studies for both comparisons. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004044-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004044-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004044-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004044-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antidepressant versus placebo, Outcome 1: Clinical response" data-id="CD004044-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antidepressant versus placebo, Outcome 1: Clinical response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antidepressant versus placebo, Outcome 2: Dropouts" data-id="CD004044-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antidepressant versus placebo, Outcome 2: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antipsychotic versus placebo, Outcome 1: Clinical response" data-id="CD004044-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antipsychotic versus placebo, Outcome 1: Clinical response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antipsychotic versus placebo, Outcome 2: Dropouts" data-id="CD004044-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Antipsychotic versus placebo, Outcome 2: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antidepressant versus antidepressant, Outcome 1: Clinical response" data-id="CD004044-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Antidepressant versus antidepressant, Outcome 1: Clinical response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antidepressant versus antidepressant, Outcome 2: Dropouts" data-id="CD004044-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Antidepressant versus antidepressant, Outcome 2: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant versus antipsychotic, Outcome 1: Clinical response" data-id="CD004044-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant versus antipsychotic, Outcome 1: Clinical response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant versus antipsychotic, Outcome 2: Dropouts" data-id="CD004044-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant versus antipsychotic, Outcome 2: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Antidepressant plus antipsychotic versus placebo, Outcome 1: Clinical response" data-id="CD004044-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Antidepressant plus antipsychotic versus placebo, Outcome 1: Clinical response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Antidepressant plus antipsychotic versus placebo, Outcome 2: Dropouts" data-id="CD004044-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Antidepressant plus antipsychotic versus placebo, Outcome 2: Dropouts</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Antidepressant plus antipsychotic versus placebo plus antipsychotic, Outcome 1: Clinical response" data-id="CD004044-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Antidepressant plus antipsychotic versus placebo plus antipsychotic, Outcome 1: Clinical response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Antidepressant plus antipsychotic versus placebo plus antipsychotic, Outcome 2: Dropouts" data-id="CD004044-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Antidepressant plus antipsychotic versus placebo plus antipsychotic, Outcome 2: Dropouts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Antidepressant plus antipsychotic versus placebo plus antidepressant, Outcome 1: Clinical response" data-id="CD004044-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Antidepressant plus antipsychotic versus placebo plus antidepressant, Outcome 1: Clinical response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Antidepressant plus antipsychotic versus placebo plus antidepressant, Outcome 2: Dropouts" data-id="CD004044-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Antidepressant plus antipsychotic versus placebo plus antidepressant, Outcome 2: Dropouts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Antidepressant plus antipsychotic versus placebo plus the same antidepressant, Outcome 1: Clinical response" data-id="CD004044-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Antidepressant plus antipsychotic versus placebo plus the same antidepressant, Outcome 1: Clinical response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004044-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/urn:x-wiley:14651858:media:CD004044:CD004044-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Antidepressant plus antipsychotic versus placebo plus the same antidepressant, Outcome 2: Dropouts" data-id="CD004044-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_t/tCD004044-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Antidepressant plus antipsychotic versus placebo plus the same antidepressant, Outcome 2: Dropouts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/media/CDSR/CD004044/image_n/nCD004044-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antidepressant compared to placebo for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant compared to placebo for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 8.40<br/>(0.50 to 142.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study defined depression response as HRSD‐17 &lt; 7</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/>(18 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.24<br/>(0.34 to 4.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000<br/>(78 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antidepressant compared to placebo for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antipsychotic compared to placebo for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antipsychotic compared to placebo for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> at least first week of study in hospital<br/><b>Intervention:</b> antipsychotic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(0.74 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Studies defined depression response as reduction in HAMD‐24 ≥ 50% at endpoint</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>316 per 1000<br/>(207 to 484) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/>(0.57 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000<br/>(268 to 508) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antipsychotic compared to placebo for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antidepressant compared to antidepressant for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant compared to antidepressant for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant<br/><b>Comparison:</b> antidepressant </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical response</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not possible due to heterogeneity between the different antidepressants used </p> <p><a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> showed that imipramine may be more effective than fluvoxamine (RR 2.10, 95% CI 1.06 to 4.17) </p> <p><a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> showed that imipramine may be more effective than mirtazapine (RR 3.00, 95% CI 1.01 to 8.95) </p> <p><a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> showed that sertraline may be more effective than paroxetine (RR 3.37, 95% CI 1.19 to 9.57) </p> <p><a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a> found no difference between fluvoxamine and venlafaxine (RR 1.50, 95% CI 0.82 to 2.75) </p> <p><a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> found no difference between imipramine and venlafaxine (RR 1.57, 95% CI 0.93 to 2.67) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004044-bbs2-0010" title="WijkstraJ , BurgerH , vanden BroekWW , BirkenhägerTK , JanzingJG , BoksMP , et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica2010;121(3):190-200. ">Wijkstra 2010</a> found no difference between imipramine and venlafaxine (RR 0.81, 95% CI 0.33 to 2.03) </p> <p><a href="./references#CD004044-bbs2-0002" title="BruijnJA , MolemanP , MulderPG , vanden BroekWW , vanHulstAM , van derMastRC , et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology1996;127(3):231-7. BruijnJA , MolemanP , MulderPG , vanden BroekWW . Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry1999;32(3):87-92. ">Bruijn 1996</a> found no difference between imipramine and mirtazapine (RR 0.50, 95% CI 0.19 to 1.31) </p> <p><a href="./references#CD004044-bbs2-0065" title="vanden BroekWW , Lely deA , MulderPGH , BirkenhägerTK , BruijnJ . Effect of antidepressant medication resistance on short-term response to ECT. Journal of Clinical Psychopharmacology2004;24(4):400-3.">van den Broek 2004a</a> found no difference between imipramine and fluvoxamine (RR 2.00, 95% CI 0.40 to 9.95) </p> <p><a href="./references#CD004044-bbs2-0011" title="ZanardiR , FranchiniL , GasperiniM , PerezJ , SmeraldiE . Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry.1996;153(12):1631-3. ">Zanardi 1996</a> found no difference between sertraline and paroxetine (RR 0.20, 95% CI 0.01 to 3.74) </p> <p><a href="./references#CD004044-bbs2-0012" title="ZanardiR , FranchiniL , SerrettiA , PerezJ , SmeraldiE . Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Journal of Clinical Psychiatry2000;61(1):26-9. ">Zanardi 2000</a> found no difference between fluvoxamine and venlafaxine (RR 0.07, 95% CI 0.00 to 1.20) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>b</sup>Downgraded one level for imprecision as CIs are consistent with appreciable benefit and appreciable harm. </p> <p><sup>c</sup>Downgraded one level for high risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antidepressant compared to antidepressant for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antidepressant compared to antipsychotic for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant compared to antipsychotic for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant<br/><b>Comparison:</b> antipsychotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antipsychotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.09<br/>(0.64 to 6.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study defined depression response as HRSD‐17 &lt; 7</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>369 per 1000<br/>(113 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.79<br/>(0.18 to 18.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/>(11 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>b</sup>Downgraded one level for imprecision as CIs are consistent with appreciable benefit and appreciable harm. </p> <p><sup>c</sup>Downgraded one level for risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antidepressant compared to antipsychotic for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> at least first week of study in hospital<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.86<br/>(1.23 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Both studies defined response as reduction in HAMD‐24 ≥ 50% at endpoint</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000<br/>(344 to 790) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.48 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>353 per 1000<br/>(226 to 555) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for for high risk of other source of bias. </p> <p><sup>b</sup>Downgraded one level for for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>d</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus antipsychotic for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo plus antipsychotic for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital (2 RCTs) or at least first week of study in hospital (2 RCTs)<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo plus antipsychotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus antipsychotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.83<br/>(1.40 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>447<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies defined response as reduction in HAMD‐24 ≥ 50% at endpoint, 1 study defined response as HAMD‐17 ≦ 10, and another study defined response as HRSD‐17 &lt; 7 </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>487 per 1000<br/>(373 to 633) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/>(0.63 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>447<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 per 1000<br/>(274 to 440) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Depression Rating Scale; <b>HRSD:</b> Hamilton Rating Scale for Depression; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other source of bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision as CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus antipsychotic for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus antidepressant for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo plus antidepressant for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo plus antidepressant </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus antidepressant</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.42<br/>(1.11 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>245<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One study defined response as HRSD‐17 &lt; 7, another study defined response as HAMD‐17 ≦ 10, another study defined response as HAMD‐17 &lt; 11, and a fourth study defined response as reduction in HRSD‐17 &gt; 50% </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>436 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>619 per 1000<br/>(484 to 784) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.55 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>245<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1,000<br/>(114 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Depression Rating Scale; <b>HRSD:</b> Hamilton Rating Scale for Depression; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for high risk of attrition bias and other source of bias in one study. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>d</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus antidepressant for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004044-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus the same antidepressant for psychotic depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antidepressant plus antipsychotic compared to placebo plus the same antidepressant for psychotic depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with psychotic depression<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> antidepressant plus antipsychotic<br/><b>Comparison:</b> placebo plus the same antidepressant </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo plus the same antidepressant</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressant plus antipsychotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical response of depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70<br/>(1.19 to 2.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One study defined response as HAMD‐17 &lt; 11, another study defined response as HRSD‐17 &lt; 7, and a third study defined response as ≧ 50% decrease in HAMD‐17 scores from baseline to study endpoint </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>596 per 1000<br/>(417 to 852) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall dropouts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.52 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>176 per 1000<br/>(88 to 349) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression remission</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in depression severity from baseline</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dropouts due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Depression Rating Scale; <b>HRSD:</b> Hamilton Rating Scale for Depression; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for high risk of other source of bias. </p> <p><sup>b</sup>Downgraded one level for high risk of publication bias. </p> <p><sup>c</sup>Downgraded one level for imprecision due to small sample size. </p> <p><sup>d</sup>Downgraded one level for imprecision due to small sample size; CIs are consistent with appreciable harm and appreciable benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Antidepressant plus antipsychotic compared to placebo plus the same antidepressant for psychotic depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/full#CD004044-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antidepressant versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.40 [0.50, 142.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.34, 4.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antidepressant versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antipsychotic versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.74, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antipsychotic versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antidepressant versus antidepressant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Imipramine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Imipramine vs mirtazapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Imipramine vs fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Fluvoxamine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Sertraline vs paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Imipramine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Imipramine vs mirtazapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Imipramine vs fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Fluvoxamine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Sertraline vs paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antidepressant versus antidepressant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antidepressant versus antipsychotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.64, 6.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.18, 18.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antidepressant versus antipsychotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Fluoxetine + olanzapine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.23, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Fluoxetine + olanzapine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.48, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo plus antipsychotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.40, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Amitriptyline + perphenazine vs perphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.61 [1.23, 10.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Fluoxetine + olanzapine vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.10, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Olanzapine + sertraline vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.21, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.63, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Amitriptyline + perphenazine vs perphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.38, 25.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Fluoxetine + olanzapine vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.59, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Olanzapine + sertraline vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.53, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo plus antipsychotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo plus antidepressant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.11, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Nortriptyline + perphenazine vs nortriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.49, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Venlafaxine + quetiapine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.13, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Amitriptyline + perphenazine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.89, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 Amitriptyline + perphenazine vs amoxapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.75, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 Venlafaxine + quetiapine vs imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.84, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.55, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Nortriptyline + perphenazine vs nortriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.26, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Venlafaxine + quetiapine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.22, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 Amitriptyline + perphenazine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.35, 8.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.4 Amitriptyline + perphenazine vs amoxapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.29, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.5 Venlafaxine + quetiapine vs imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.38, 3.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo plus antidepressant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004044-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo plus the same antidepressant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.19, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.52, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Nortriptyline + perphenazine vs nortriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.26, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Venlafaxine + quetiapine vs venlafaxine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.33, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.3 Amitriptyline + perphenazine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.35, 8.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Antidepressant plus antipsychotic versus placebo plus the same antidepressant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004044.pub5/references#CD004044-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004044.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004044-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004044-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004044-note-0020">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004044-note-0018">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD004044-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD004044-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004044-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD004044-note-0015">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD004044-note-0013">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004044-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004044-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004044\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004044\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004044\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004044\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004044\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004044.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004044.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004044.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004044.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004044.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714429831"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004044.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714429835"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004044.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6e753ce39377',t:'MTc0MDcxNDQzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 